AMA RESOLUTION 235 November 2018 INAPPROPRIATE USE OF CDC Guidelines FOR PRESCRIBING OPIOIDS (Entire Document)
“Resolution 235 asks that our AMA applaud the CDC for its efforts to prevent the incidence of new cases of opioid misuse, addiction, and overdose deaths; and be it further, that no entity should use MME thresholds as anything more than guidance and that MME thresholds should not be used to completely prohibit the prescribing of, or the filling of prescriptions for, medications used in oncology care, palliative medicine care, and addiction medicine care: and be it further, that our AMA communicate with the nation’s largest pharmacy chains and pharmacy benefit managers to recommend that they cease and desist with writing threatening letters to physicians and cease and desist with presenting policies, procedures and directives to retail pharmacists that include a blanket proscription against filling prescriptions for opioids that exceed certain numerical thresholds without taking into account the diagnosis and previous response to treatment for a patient and any clinical nuances that would support such prescribing as falling within standards of good quality patient care; and be it further, that AMA Policy opposing the legislating of numerical limits on medication dosage, duration of therapy, numbers of pills/tablets, etc., be reaffirmed; and be it further, that physicians should not be subject to professional discipline or loss of board certification or loss of clinical privileges simply for prescribing opioids at a quantitative level that exceeds the MME thresholds found in the CDC Guidelines; and be it further, that our AMA encourage the Federation of State Medical Boards and its member boards, medical specialty societies, and other entities to develop improved guidance on management of pain and management of potential withdrawal syndromes and other aspects of patient care for “legacy patients” who may have been treated for extended periods of time with high-dose opioid therapy for chronic non-malignant pain.
RESOLVED, that our American Medical Association (AMA) applaud the Centers for Disease Control and Prevention (CDC) for its efforts to prevent the incidence of new cases of opioid misuse, addiction, and overdose deaths
RESOLVED, that our AMA actively continue to communicate and engage with the nation’s largest pharmacy chains, pharmacy benefit managers, National Association of Insurance Commissioners, Federation of State Medical Boards, and National Association of Boards of Pharmacy in opposition to communications being sent to physicians that include a blanket proscription against filing prescriptions for opioids that exceed numerical thresholds without taking into account the diagnosis and previous response to treatment for a patient and any clinical nuances that would support such prescribing as falling within standards of good quality patient care.
RESOLVED, that our AMA affirms that some patients with acute or chronic pain can benefit from taking opioid pain medications at doses greater than generally recommended in the CDC Guideline for Prescribing Opioids for Chronic Pain and that such care may be medically necessary and appropriate, and be it further
RESOLVED, that our AMA advocate against misapplication of the CDC Guideline for Prescribing Opioids by pharmacists, health insurers, pharmacy benefit managers, legislatures, and governmental and private regulatory bodies in ways that prevent or limit patients’ medical access to opioid analgesia, and be it further
RESOLVED, that our AMA advocate that no entity should use MME (morphine milligram equivalents) thresholds as anything more than guidance, and physicians should not be subject to professional discipline, loss of board certification, loss of clinical privileges, criminal prosecution, civil liability, or other penalties or practice limitations solely for prescribing opioids at a quantitative level above the MME thresholds found in the CDC Guideline for Prescribing Opioids.””
Pain Management Best Practices Inter-Agency Task Force - Draft Report on Pain Management Best Practices: Updates, Gaps, Inconsistencies, and Recommendations Official Health and Human Services Department Released December 2018
“The Comprehensive Addiction and Recovery Act (CARA) of 2016 led to the creation of the Pain Management Best Practices Inter-Agency Task Force (Task Force), whose mission is to determine whether gaps in or inconsistencies between best practices for acute and chronic pain management exist and to propose updates and recommendations to those best practices. The Task Force consists of 29 experts who have significant experience across the disciplines of pain management, patient advocacy, substance use disorders, mental health, and minority health.”
In addition to identifying approximately 60 gaps in clinical best practices and the current treatment of pain in the United States, HHS PMTF provided recommendations for each of these major areas of concern. In alignment with their original charter, the PMTF will submit these recommendations to Congress to become our ‘National Pain Policy’. The 60+ gaps and inconsistencies with their recommendations will serve to fill gaps in pain treatment at both the state and federal level; and the overwhelming consensus was that the treatment of pain should be multimodal and completely individualized based on the individual patient. The heart of each recommendation in each section was a resounding call for individualization for each patient, in regards to both non-pharmacological and pharmacological modalities; including individualizations in both opioid and non-opioid pharmacological treatments.
While each of the gap+recommendation sections of what is poised to become our national pain policy is extremely important, one that stands out the most (in regards to opioid prescribing) is the Stigma section. Contained in this section is one of the core statements that shows our Health and Human Services agency - the one that should have always been looked to and followed - knew the true depth of the relationship (or lack of) between the overdose crisis and compassionate prescribing to patients with painful conditions:
“The national crisis of illicit drug use, with overdose deaths, is confused with appropriate therapy for patients who are being treated for pain. This confusion has created a stigma that contributes to raise barriers to proper access to care.”
The recommendation that follows - “Identify strategies to reduce stigma in opioid use so that it is never a barrier to patients receiving appropriate treatment, with all cautions and considerations for the management of their chronic pain conditions” - illustrates an acknowledgment by the top health agency of the federal government that the current national narrative conflating and confusing compassionate treatment of pain with illicit drug use, addiction, and overdose death is incorrect and only serving to harm patients.
Since March of 2016 when the CDC Guidelines were released, advocates, patients, clinicians, stakeholders, and others, have began pointing out limitations and unintended consequences as they emerged. In order to address the unintended consequences emerging from the CDC Guidelines, this task force was also charged with review of these guidelines; from expert selection, evidence selection, creation, and continuing to current misapplication in order to provide recommendations to begin to remedy these issues.
“A commentary by Busse et al. identified several limitations to the CDC guideline related to expert selection, evidence inclusion criteria, method of evidence quality grading, support of recommendations with low-quality evidence, and instances of vague recommendations. In addition, the CDC used the criterion of a lack of clinical trials with a duration of one year or longer as lack of evidence for the clinical effectiveness of opioids, whereas Tayeb et al. found that that was true for all common medication and behavioral therapy studies.
Interpretation of the guideline, in addition to some gaps in the guideline, have led to unintended consequences, some of which are the result of misapplication or misinterpretation of the CDC guideline.
However, at least 28 states have enacted legislation related to opioid prescription limits, and many states and organizations have implemented the guideline without recognizing that the intended audience was PCPs; have used legislation for what should be medical decision making by healthcare professionals; and have applied them to all physicians, dentists, NPs, and PAs, including pain specialists.441–444 Some stakeholders have interpreted the guideline as intended to broadly reduce the amount of opioids prescribed for treating pain; some experts have noted that the guideline emphasizes the risk of opioids while minimizing the benefit of this medication class when properly managed.”
“The CDC guideline was not intended to be model legislation for state legislators to enact”
“In essence, clinicians should be able to use their clinical judgment to determine opioid duration for their patients”
https://www.hhs.gov/ash/advisory-committees/pain/reports/2018-12-draft-report-on-updates-gaps-inconsistencies-recommendations/index.html
HHS Review of 2016 CDC Guidelines for responsible opioid prescribing
The Pain Management Task Force addressed 8 areas that are in need of update or expansion with recommendations to begin remediation for each problem area:
Lack of high-quality data exists for duration of effectiveness of opioids for chronic pain; this has been interpreted as a lack of benefit Conduct studies Focus on patient variability and response for effectiveness of opioids; use real-world applicable trials
Absence of criteria for identifying patients for whom opioids make up significant part of their pain treatment Conduct clinical trials and/or reviews to identify sub-populations of patients where long-term opioid treatment is appropriate
Wide variation in factors that affect optimal dose of opioids Consider patient variables for opioid therapy: Respiratory compromise Patient metabolic variables Differences in opioid medications/plasma concentrations Preform comprehensive initial assessment it’s understanding of need for comprehensive reevaluations to adjust dose Give careful considerations to patients on opioid pain regimen with additional risk factors for OUD
Specific guidelines for opioid tapering and escalation need to be further clarified A thorough assessment of risk-benefit ratio should occur whenever tapering or escalation of dose This should include collaboration with patient whenever possible Develop taper or dose escalation guidelines for sub-populations that include consideration of their comorbidities When benefit outweighs the risk, consider maintaining therapy for stable patients on long term opioid therapy
Causes of worsening pain are not often recognized or considered. Non-tolerance related factors: surgery, flares, increased physical demands, or emotional distress Avoid increase in dose for stable patient (2+ month stable dose) until patient is re-evaluated for underlying cause of elevated pain or possible OUD risk Considerations to avoid dose escalation include: Opioid rotation Non-opioid medication Interventional strategies Cognitive behavior strategies Complementary and integrative health approaches Physical therapy
In patients with chronic pain AND anxiety or spasticity, benzodiazepine co-prescribed with opioids still have clinical value; although the risk of overdose is well established When clinically indicated, co-prescription should be managed by specialist who have knowledge, training, and experience with co-prescribing. When co-prescribed for anxiety or SUD collaboration with mental health should be considered Develop clinical practice guidelines focused on tapering for co-prescription of benzodiazepines and opioids
The risk-benefit balance varies for individual patients. Doses >90MME may be favorable for some where doses <90MME may be for other patients due to individual patient factors. Variability in effectiveness and safety between high and low doses of opioids are not clearly defined. Clinicians should use caution with higher doses in general Using carefully monitored trial with frequent monitoring with each dose adjustment and regular risk reassessment, physicians should individualize doses, using lowest effective opioid dose that balances benefit, risk, and adverse reactions Many factors influence benefits and risk, therefore, guidance of dose should not be applied as strict limits. Use established and measurable goals: Functionality ADL Quality of Life
Duration of pain following acute and severely painful event is widely variable Appropriate duration is best considered within guidelines, but is ultimately determined by treating clinician. CDC recommendation for duration should be emphasized as guidance only with individualized patient care as the goal Develop acute pain management guidelines for common surgical procedures and traumas To address variability and provide easy solution, consideration should be given to partial refill system
Human Rights Watch December 2018 (Excerpt from 109 page report)
“If harms to chronic pain patients are an unintended consequence of policies to reduce inappropriate prescribing, the government should seek to immediately minimize and measure the negative impacts of these policies. Any response should avoid further stigmatizing chronic pain patients, who are increasingly associated with — and sometimes blamed for — the overdose crisis and characterized as “drug seekers,” rather than people with serious health problems that require treatment.
Top government officials, including the President, have said the country should aim for drastic cutbacks in prescribing. State legislatures encourage restrictions on prescribing through new legislation or regulations. The Drug Enforcement Administration (DEA) has investigated medical practitioners accused of overprescribing or fraudulent practice. State health agencies and insurance companies routinely warn physicians who prescribe more opioids than their peers and encourage them to reduce prescribing. Private insurance companies have imposed additional requirements for covering opioids, some state Medicaid programs have mandated tapering to lower doses for patients, and pharmacy chains are actively trying to reduce the volumes of opioids they dispense.
The medical community at large recognized that certain key steps were necessary to tackle the overdose crisis: identifying and cracking down on “pill mills” and reducing the use of opioids for less severe pain, particularly for children and adolescents. However, the urgency to tackle the overdose crisis has put pressure on physicians in other potentially negative ways: our interviews with dozens of physicians found that the atmosphere around prescribing for chronic pain had become so fraught that physicians felt they must avoid opioid analgesics even in cases when it contradicted their view of what would provide the best care for their patients. In some cases, this desire to cut back on opioid prescribing translated to doctors tapering patients off their medications without patient consent, while in others it meant that physicians would no longer accept patients who had a history of needing high-dose opioids.
The consequences to patients, according to Human Rights Watch research, have been catastrophic.”
[https://www.hrw.org/report/2018/12/18/not-allowed-be-compassionate/chronic-pain-overdose-crisis-and-unintended-harms-us](
Opioid Prescribing Workgroup December 2018
This is material from the Board of Scientific Counselors in regards to their December 12, 2018 meeting that culminated the works of a project titled the “Opioid Prescribing Estimates Project.” This project is a descriptive study that is examining opioid prescribing patterns at a population level. Pain management is a very individualized process that belongs with the patient and provider. The Workgroup reviewed work done by CDC and provided additional recommendations.
SUMMARY There were several recurrent themes throughout the sessions.
Repeated concern was voiced from many Workgroup members that the CDC may not be able to prevent conclusions from this research (i.e. the benchmarks, developed from limited data) from being used by states or payors or clinical care systems to constrain clinical care or as pay-for- performance standards – i.e. interpreted as “guidelines”. This issue was raised by several members on each of the four calls, raising the possibility that providers or clinical systems could thus be incentivized against caring for patients requiring above average amounts of opioid medication.
Risk for misuse of the analysis. Several members expressed concerns that this analysis could be interpreted as guidance by regulators, health plans, or clinical care systems. Even though the CDC does not plan to issue this as a guideline, but instead as research, payors and clinical care systems searching for ways to reign in opioid prescribing may utilize CDC “benchmarks” to establish pay-for-performance or other means to limit opioid prescribing. Such uses of this work could have the unintended effect of incentivizing providers against caring for patients reliant upon opioids.
…It was also noted that, in order to obtain sufficient granularity to establish the need for, dosage, and duration of opioid therapy, it would be necessary to have much more extensive electronic medical record data. In addition, pain and functional outcomes are absent from the dataset, but were felt to be important when considering risk and benefit of opioids.
...Tapering: Concerns about benchmarks and the implications for tapering were voiced. If tapering occurs, guidance was felt to be needed regarding how, when, in whom tapering should occur. This issue was felt to be particularly challenging for patients on chronic opioids (i.e. “legacy” patients). In addition, the importance of measuring risk and benefit of tapering was noted. Not all high-dose patient populations benefit from tapering.
Post-Surgical Pain
General comments. Workgroup members noted that most patients prescribed opioids do not experience adverse events, including use disorder. Many suggested that further discussion of opioids with patients prior to surgery was important, with an emphasis on expectations and duration of treatment. A member suggested that take-back programs would be more effective than prescribing restrictions.
Procedure-related care. Members noted that patient factors may drive opioid need more than characteristics of a procedure.
Patient-level factors. Members noted that opioid-experienced patients should be considered differently from opioid-inexperienced patients, due to tolerance.
Chronic Pain
It was noted that anything coming out of the CDC might be considered as guidelines and that this misinterpretation can be difficult to counter. There was extensive discussion of the 50 and 90 MME levels included in the CDC Guidelines. It was recommended that the CDC look into the adverse effects of opioid tapering and discontinuation, such as illicit opioid use, acute care utilization, dropping out of care, and suicide. It was also noted that there are major gaps in guidelines for legacy patients, patients with multiple diagnoses, pediatric and geriatric patients, and patients transitioning to lower doses.
There were concerns that insufficient clinical data will be available from the dataset to appropriately consider the individual-level factors that weigh into determination of opioid therapy. The data would also fail to account for the shared decision-making process involved in opioid prescribing for chronic pain conditions, which may be dependent on primary care providers as well as ancillary care providers (e.g. physical therapists, psychologists, etc).
Patient-level factors. Members repeatedly noted that opioid-experienced patients should be considered differently from opioid-experienced patients, due to tolerance.
Members noted that the current CDC guidelines have been used by states, insurance companies, and some clinical care systems in ways that were not intended by the CDC, resulting in cases of and the perception of patient abandonment. One option raised in this context was to exclude patients on high doses of opioids, as those individuals would be qualitatively different from others. A variant of this concern was about management of “legacy” patients who are inherited on high doses of opioids. Members voiced concerns that results of this work has caused harm to patients currently reliant upon opioids prescribed by their providers.
Acute Non-Surgical Pain
Patient-level factors. Members felt that opioid naïve versus experienced patients might again be considered separately, as opioid requirements among those experienced could vary widely.
...Guidelines were also noted to be often based on consensus, which may be incorrect.
Cancer-Related and Palliative Care Pain
It was noted that the CDC guidelines have been misinterpreted to create a limit to the dose of opioids that can be provided to people at all stages of cancer and its treatment. It was also noted that the cancer field is rapidly evolving, with immunotherapy, CAR-T, and other novel treatments that affect response rates and limit our ability to rely upon historical data in establishing opioid prescribing benchmarks.
Concern that data would not be able to identify all of the conditions responsible for pain in a patient with a history of cancer (e.g. people who survive cancer but with severe residual pain). Further, it was noted that certain complications of cancer and cancer treatment may require the least restrictive long-term therapy with opioids.
The definition of palliative care was also complicated and it was suggested that this include patients with life-limiting conditions.
Overall, it was felt that in patients who may not have long to live, and/or for whom returning to work is not a possibility, higher doses of opioids may be warranted.
https://www.cdc.gov/injury/pdfs/bsc/NCIPC_BSC_OpioidPrescribingEstimatesWorkgroupReport_December-12_2018-508.pdf
CDC Scientists Anonymous ‘Spider Letter’ to CDC
Carmen S. Villar, MSW Chief of Staff Office of the Director MS D­14 Centers for Disease Control and Prevention (CDC) 1600 Clifton Road Atlanta, Georgia 30329­-4027
August 29, 2016
Dear Ms. Villar:
We are a group of scientists at CDC that are very concerned about the current state of ethics at our agency. It appears that our mission is being influenced and shaped by outside parties and rogue interests. It seems that our mission and Congressional intent for our agency is being circumvented by some of our leaders. What concerns us most, is that it is becoming the norm and not the rare exception. Some senior management officials at CDC are clearly aware and even condone these behaviors. Others see it and turn the other way. Some staff are intimidated and pressed to do things they know are not right. We have representatives from across the agency that witness this unacceptable behavior. It occurs at all levels and in all of our respective units. These questionable and unethical practices threaten to undermine our credibility and reputation as a trusted leader in public health. We would like to see high ethical standards and thoughtful, responsible management restored at CDC. We are asking that you do your part to help clean up this house!
It is puzzling to read about transgressions in national media outlets like USA Today, The Huffington Post and The Hill. It is equally puzzling that nothing has changed here at CDC as a result. It’s business as usual. The litany of issues detailed over the summer are of particular concern:
Recently, the National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP) has been implicated in a “cover up” of inaccurate screening data for the Wise Woman (WW) Program. There was a coordinated effort by that Center to “bury” the fact that screening numbers for the WW program were misrepresented in documents sent to Congress; screening numbers for 2014 and 2015 did not meet expectations despite a multi­million dollar investment; and definitions were changed and data “cooked” to make the results look better than they were. Data were clearly manipulated in irregular ways. An “internal review” that involved staff across CDC occurred and its findings were essentially suppressed so media and/or Congressional staff would not become aware of the problems. Now that both the media and Congresswoman DeLauro are aware of these issues, CDC staff have gone out of their way to delay FOIAs and obstruct any inquiry. Shouldn’t NCCDPHP come clean and stop playing games? Would the ethical thing be to answer the questions fully and honestly. The public should know the true results of what they paid for, shouldn’t they?
Another troubling issue at the NCCDPHP are the adventures of Drs. Barbara Bowman and Michael Pratt (also detailed in national media outlets). Both seemed to have irregular (if not questionable) relationships with Coca­Cola and ILSI representatives. Neither of these relationships were necessary (or appropriate) to uphold our mission. Neither organization added any value to the good work and science already underway at CDC. In fact, these ties have now called into question and undermined CDC’s work. A cloud has been cast over the ethical and excellent work of scientists due to this wanton behavior. Was cultivating these relationships worth dragging CDC through the mud? Did Drs. Bowman and Pratt have permission to pursue these relationships from their supervisor Dr. Ursula Bauer? Did they seek and receive approval of these outside activities? CDC has a process by which such things should be vetted and reported in an ethics review, tracking and approval system (EPATS). Furthermore, did they disclose these conflicts of interest on their yearly OGE 450 filing. Is there an approved HHS 520, HHS 521 or “Request for Official Duty Activities Involving an Outside Organization” approved by Dr. Bauer or her Deputy Director Ms. Dana Shelton? An August 28, 2016 item in The Hill details these issues and others related to Dr. Pratt.
It appears to us that something very strange is going on with Dr. Pratt. He is an active duty Commissioned Corps Officer in the USPHS, yet he was “assigned to” Emory University for a quite some time. How and under what authority was this done? Did Emory University pay his salary under the terms of an IPA? Did he seek and receive an outside activity approval through EPATS and work at Emory on Annual Leave? Formal supervisor endorsement and approval (from Dr. Bauer or Ms. Shelton) is required whether done as an official duty or outside activity.
If deemed official, did he file a “Request for Official Duty Activities Involving an Outside Organization” in EPATS? Apparently Dr. Pratt’s position at Emory University has ended and he has accepted another position at the University of California ­ San Diego? Again, how is this possible while he is still an active duty USPHS Officer. Did he retire and leave government service? Is UCSD paying for his time via an IPA? Does he have an outside activity approval to do this? Will this be done during duty hours? It is rumored that Dr. Pratt will occupy this position while on Annual Leave? Really? Will Dr. Pratt be spending time in Atlanta when not on Annual Leave? Will he make an appearance at NCCDPHP (where he hasn’t been seen for months). Most staff do not enjoy such unique positions supported and approved by a Center Director (Dr. Bauer). Dr. Pratt has scored a sweet deal (not available to most other scientists at CDC). Concerns about these two positions and others were recently described in The Huffington Post and The Hill. His behavior and that of management surrounding this is very troubling.
Finally, most of the scientists at CDC operate with the utmost integrity and ethics. However, this “climate of disregard” puts many of us in difficult positions. We are often directed to do things we know are not right. For example, Congress has made it very clear that domestic funding for NCCDPHP (and other CIOs) should be used for domestic work and that the bulk of NCCDPHP funding should be allocated to program (not research). If this is the case, why then is NCCDPHP taking domestic staff resources away from domestic priorities to work on global health issues? Why in FY17 is NCCDPHP diverting money away from program priorities that directly benefit the public to support an expensive research FOA that may not yield anything that benefits the public? These actions do not serve the public well. Why is nothing being done to address these problems? Why has the CDC OD turned a blind eye to these things. The lack of respect for science and scientists that support CDC’s legacy is astonishing.
Please do the right thing. Please be an agent of change.
Respectfully,
CDC Spider (CDC Scientists Preserving Integrity, Diligence and Ethics in Research)
https://usrtk.org/wp-content/uploads/2016/10/CDC_SPIDER_Letter-1.pdf
January 13, 2016
Thomas Frieden, MD, MPH Director Centers for Disease Control and Prevention 1600 Clifton Road Atlanta, GA 30329-4027
Re: Docket No. CDC-2015-0112; Proposed 2016 Guideline for Prescribing Opioids for Chronic Pain
Dear Dr. Frieden:
There is no question that there is an opioid misuse epidemic and that efforts need to be made to control it. The Centers for Disease Control and Prevention (CDC) is applauded for its steps to undertake this lofty effort. However, based on the American Academy of Family Physicians’ (AAFP’s) review of the guideline, it is apparent that the presented recommendations are not graded at a level consistent with currently available evidence. The AAFP certainly wants to promote safe and appropriate prescribing of opioids; however, we recommend that the CDC still adhere to the rigorous standards for reliable and trustworthy guidelines set forth by the Institute of Medicine (IOM). The AAFP believes that giving a strong recommendation derived from generalizations based on consensus expert opinion does not adhere to evidence-based standards for developing clinical guideline recommendations.
The AAFP’s specific concerns with the CDC’s methodology, evidence base, and recommendations are outlined below.
Methodology and Evidence Base
All of the recommendations are based on low or very low quality evidence, yet all but one are Category A (or strong) recommendations. The guideline states that in the GRADE methodology "a particular quality of evidence does not necessarily imply a particular strength of recommendation." While this is true, it applies when benefits significantly outweigh harms (or vice versa). When there is insufficient evidence to determine the benefits and harms of a recommendation, that determination should not be made.
When evaluating the benefits of opioids, the evidence review only included studies with outcomes of at least one year. However, studies with shorter intervals were allowed for analysis of the benefits of nonopioid treatments. The guideline states that no evidence shows long-term benefit of opioid use (because there are few studies), yet the guideline reports "extensive evidence" of potential harms, even though these studies were of low quality. The accompanying text also states "extensive evidence" of the benefits of non-opioid treatments, yet this evidence was from shorter term studies, was part of the contextual review rather than the clinical systematic review, and did not compare non- opioid treatments to opioids.
The patient voice and preferences were not explicitly included in the guideline. This raises concerns about the patient-centeredness of the guideline.
https://www.aafp.org/dam/AAFP/documents/advocacy/prevention/risk/LT-CDC-OpioidGuideline011516.pdf The Myth of Morphine Equivalent Daily Dosage Medscape Neuro Perspective
For far too many years, pain researchers and clinicians have relied on the concept of the morphine equivalent daily dosage (MEDD), or some variant of it, as a means of comparing the "relative corresponding quantity" of the numerous opioid molecules that are important tools in the treatment of chronic pain.
...And, most unfortunately, opioid prescribing guideline committees have relied on this concept as a means of placing (usually arbitrary) limits on the levels of opioids that a physician or other clinician should be allowed to prescribe. Although these guidelines typically bill themselves as "voluntary," their chilling effect on prescribers and adaptation into state laws[2] makes calling them "voluntary" disingenuous.
Although some scientists and clinicians have been questioning the conceptual validity of MEDD for several years, a recent study[3] has indicated that the concept is unequivocally flawed—thereby invalidating its use empirically and as a tool in prescribing guideline development.
The authors used survey data from pharmacists, physicians, nurse practitioners, and physician assistants to estimate daily morphine equivalents and found great inconsistency in their conversions of hydrocodone, fentanyl transdermal patches, methadone, oxycodone, and hydromorphone—illustrating the potential for dramatic underdosing or, in other cases, fatal overdosing.
Patients with chronic pain (particularly that of noncancer origin) who are reliant on opioid analgesia are already sufficiently stigmatized and marginalized[7] to allow this type of practice to continue to be the norm.
Although the use of MEDD in research and, to a greater extent, in practice, is probably due to unawareness of its inaccuracy, we posit that the use of MEDD by recent opioid guideline committees (eg, the Washington State Opioid Guideline Committee[8] and the Centers for Disease Control and Prevention Guideline Committee[9]) in the drafting of their guidelines is based more heavily on disregarding available evidence rather than ignorance. Furthermore, their misconduct in doing so has been more pernicious than the use of MEDD by researchers and individual clinicians, because these guidelines widely affect society as a whole as well as individual patients with persistent pain syndromes. We opine that these committees are strongly dominated by the antiopioid community, whose agenda is to essentially restrict opioid access—irrespective of the lack of data indicating that opioids cannot be a useful tool in the comprehensive treatment of carefully selected and closely monitored patients with chronic pain.
Above 100% extracted from: Medscape Journal Brief https://www.medscape.com/viewarticle/863477_2
Actual Study https://www.dovepress.com/the-medd-myth-the-impact-of-pseudoscience-on-pain-research-and-prescri-peer-reviewed-article-JPR
Are Non-Opioid Medications Superior in Treatment of Pain than Opioid Pain Medicine? Ice Cream Flavor Analogy...
In the Oxford University Press, a November 2018 scientific white paper[5] was released that examined the quality of one of the primary studies that have been used to justify the urgent call to drastically reduce opioid pain medication prescribing while claiming that patients are not being harmed in the process.
The study is commonly referred to as ‘the Krebs study’. “The authors concluded that treatment with opioids was not superior to treatment with non opioid medications for improving pain-related function over 12 months.”
Here is an excerpt from the first paragraph of the design section (usually behind a paywall) from the Krebs study that gives the first hint of the bias that led to them to ‘prove’ that opioids were not effective for chronic pain:

“The study was intended to assess long-term outcomes of opioids compared with non opioid medications for chronic pain. The patient selection, though, specifically excluded patients on long-term opioid therapy.” 

Here is an analogy given in the Oxford Journal white paper to illustrate how the study design was compromised:
If I want to do a randomized control study about ice cream flavor preferences (choices being: vanilla, chocolate, or no preference), the results could be manipulated as follows based on these scenarios:
Scenario A: If a study was done that included only current ice-cream consumers, the outcome would certainly be vanilla or chocolate, because of course they have tried it and know which they like.
Scenario B: If a study was done that included all consumers of all food, then it can change the outcome. If the majority of study participants do not even eat ice-cream, than the result would certainly be ‘no preference’. If the majority do eat ice-cream it would likely be ‘chocolate’. Although this study is wider based, it still does not reflect real world findings.
Scenario C: In an even more extreme example, if this same study is conducted excluding anyone who has ever ate ice-cream at all, then the conclusion will again be ‘no preference’ and the entire study/original question becomes so ludicrous that there is no useful information to be extracted from this study and one would logically question why this type of study would even be conducted (although we know the answer to that)
Scenario C above is how the study that has been used to shift the attitudes towards the treatment of pain in our nation's medical community was designed. “One has to look deep into the study to find that they began with 9403 possible patients and excluded 3836 of them just because they had opioids in their EMR. In the JAMA article, they do not state these obvious biases and instead begin the explanation of participants stating they started with 4485 patients and excluded 224 who were opioid or benzo users.” That is the tip of the iceberg to how it is extremely misleading. The Oxford white paper goes into further detail of the studies “many flaws and biases (including the narrow focus on conditions that are historically known to respond poorly to opioid medication management of pain)”, but the study design and participant selection criteria is enough to discredit this entire body of work. Based on study design alone, regardless of what happened next, the result would be that opioids are no more effective than NSAIDs and other non-opioid alternatives.
The DEA Is Fostering a Bounty Hunter Culture in its Drug Diversion Investigators[8]
A Good Man Speaks Truth to Power January 2019
Because I write and speak widely on public health issues and the so-called “opioid crisis”, people frequently send me references to others’ work. One of the more startling articles I’ve seen lately was published November 20, 2018 in Pharmacy Times. It is titled “Should We Believe Patients With Pain?”[9]. The unlikely author is Commander John Burke, “a 40-year veteran of law enforcement, the past president of the National Association of Drug Diversion Investigators, and the president and cofounder of the International Health Facility Diversion Association.”
The last paragraph of Commander Burke’s article is worth repeating here.
“Let’s get back to dealing with each person claiming to be in legitimate pain and believe them until we have solid evidence that they are scamming the system. If they are, then let’s pursue them through vigorous prosecution, but let’s not punish the majority of people receiving opioids who are legitimate patients with pain.”
This seems a remarkable insight from anyone in law enforcement — especially from one who has expressed this view in both Pain News Network, and Dr Lynn Webster’s video “The Painful Truth”. Recognizing Commander Burke’s unique perspective, I followed up by phone to ask several related questions. He has granted permission to publish my paraphrases of his answers here.
“Are there any available source documents which establish widely accepted standards for what comprises “over-prescription?” as viewed by diversion investigators?” Burke’s answer was a resounding “NO”. Each State and Federal Agency that investigates doctors for potentially illegal or inappropriate opioid prescribing is pretty much making up their own standards as they go. Some make reference to the 2016 CDC Guidelines, but others do not.

1. “Thousands of individual doctors have left pain management practice in recent years due to fears they may be investigated, sanctioned, and lose their licenses if they continue to treat patients with opioid pain relievers.. Are DEA and State authorities really pursuing the worst “bad actors”, or is something else going on?

Burke’s answer: “Regulatory policy varies greatly between jurisdictions. But a hidden factor may be contributing significantly to the aggressiveness of Federal investigators. Federal Agencies may grant financial bonuses to their in-house diversion investigators, based on the volume of fines collected from doctors, nurse practitioners, PAs and others whom they investigate.

"No law enforcement agency at any level should be rewarded with monetary gain and/or promotion due to their work efforts or successes. This practice has always worried me with Federal investigators and is unheard of at the local or state levels of enforcement.”

Commander Burke’s revelation hit me like a thunder-clap. It would explain many of the complaints I have heard from doctors who have been “investigated” or prosecuted. It’s a well known principle that when we subsidize a behavior, we get more of it. Financial rewards to investigators must inevitably foster a “bounty hunter” mentality in some. It seems at least plausible that such bonuses might lead DEA regulators to focus on “low hanging fruit” among doctors who may not be able to defend themselves without being ruined financially. The practice is at the very least unethical. Arguably it can be corrupting.
I also inquired concerning a third issue:

1. I read complaints from doctors that they have been pursued on trumped-up grounds, coerced and denied appropriate legal defense by confiscation of their assets – which are then added to Agency funds for further actions against other doctors. Investigations are also commonly announced prominently, even before indictments are obtained – a step that seems calculated to destroy the doctor’s practice, regardless of legal outcomes. Some reports indicate that DEA or State authorities have threatened employees with prosecution if they do not confirm improper practices by the doctor. Do you believe such practices are common?”

Burke’s answer: “I hear the same reports you do – and the irony is that such tactics are unnecessary. Lacking an accepted standard for over-prescribing, the gross volume of a doctor’s prescriptions or the dose levels prescribed to their patients can be poor indicators of professional misbehavior. Investigators should instead be looking into the totality of the case, which can include patient reports of poor doctor oversight, overdose-related hospital admissions, and patterns of overdose related deaths that may be linked to a “cocktail” of illicit prescribing. Especially important can be information gleaned from confidential informants – with independent verification – prior patients, and pharmacy information.”

No formal legal prosecution should ever proceed from the testimony of only one witness — even one as well informed as Commander John Burke. But it seems to me that it is high time for the US Senate Judiciary Committee to invite the testimony of others in open public hearings, concerning the practice of possible bounty hunting among Federal investigators.
C50 Patient, Civil Rights Attorney, Maine Department of Health, and Maine Legislature Collaborative Enacted Definition of Palliative Care
One suggestion that our organization would like to make is altering the definition of “palliative care” in such a manner that it can include high-impact or intractable patients; those who are not dying this year, but our lives have been shattered and/or shortened by our diseases and for whom Quality of Life should be the focus. Many of our conditions may not SIGNIFICANTLY shorten my life, therefore I could legitimately be facing 30-40 years of severe pain with little relief; that is no way to live and therefore the concern is a rapidly increasing suicide rate.
This is a definition that one of our coalition members with a civil rights attorney and the Maine Department of Health agreed upon and legislators enacted into statues in Maine. This was in response to a 100mme restriction. This attorney had prepared a lawsuit based on the Americans with Disability Act that the Department of Health in Maine agreed was valid; litigation was never the goal, it was always patient-centered care.
A. "Palliative care" means patient-centered and family-focused medical care that optimizes quality of life by anticipating, preventing and treating suffering caused by a medical illness or a physical injury or condition that substantially affects a patient's quality of life, including, but not limited to, addressing physical, emotional, social and spiritual needs; facilitating patient autonomy and choice of care; providing access to information; discussing the patient's goals for treatment and treatment options, including, when appropriate, hospice care; and managing pain and symptoms comprehensively. Palliative care does not always include a requirement for hospice care or attention to spiritual needs. B. "Serious illness" means a medical illness or physical injury or condition that substantially affects quality of life for more than a short period of time. "Serious illness" includes, but is not limited to, Alzheimer's disease and related dementias, lung disease, cancer, heart, renal or liver failure and chronic, unremitting or intractable pain such as neuropathic pain.
Here is the link to the most recent update, including these definitions within the entire statute: https://legislature.maine.gov/statutes/22/title22sec1726.html?fbclid=IwAR0dhlwEh56VgZI9HYczdjdyYoJGpMdA9TuuJLlQrO3AsSljIZZG0RICFZc
January 23, 2019
Dear Pharmacists,
The Board of Pharmacy has had an influx of communication concerning patients not able to get controlled substance prescriptions filled for various reasons, even when signs of forgery or fraudulence were not presented. As a result of the increased “refusals to fill,” the board is issuing the following guidance and reminders regarding the practice of pharmacy and dispensing of controlled substances:

1. Pharmacists must use reasonable knowledge, skill, and professional judgment when evaluating whether to fill a prescription. Extreme caution should be used when deciding not to fill a prescription. A patient who suddenly discontinues a chronic medication may experience negative health consequences;
   
2. Part of being a licensed healthcare professional is that you put the patient first. This means that if a pharmacist has any concern regarding a prescription, they should attempt to have a professional conversation with the practitioner to resolve those concerns and not simply refuse the prescription. Being a healthcare professional also means that you use your medication expertise during that dialogue in offering advice on potential alternatives, changes in the prescription strength, directions etc. Simply refusing to fill a prescription without trying to resolve the concern may call into question the knowledge, skill or judgment of the pharmacist and may be deemed unprofessional conduct;
   
3. Controlled substance prescriptions are not a “bartering” mechanism. In other words, a pharmacist should not tell a patient that they have refused to fill a prescription and then explain that if they go to a pain specialist to get the same prescription then they will reconsider filling it. Again, this may call into question the knowledge, skill or judgment of the pharmacist;
   
4. Yes, there is an opioid crisis. However, this should in no way alter our professional approach to treatment of patients in end-of-life or palliative care situations. Again, the fundamentals of using our professional judgment, skill and knowledge of treatments plays an integral role in who we are as professionals. Refusing to fill prescriptions for these patients without a solid medical reason may call into question whether the pharmacist is informed of current professional practice in the treatment of these medical cases.
   
5. If a prescription is refused, there should be sound professional reasons for doing so. Each patient is a unique medical case and should be treated independently as such. Making blanket decisions regarding dispensing of controlled substances may call into question the motivation of the pharmacist and how they are using their knowledge, skill or judgment to best serve the public.
   

As a professional reminder, failing to practice pharmacy using reasonable knowledge, skill, competence, and safety for the public may result in disciplinary actions under Alaska statute and regulation. These laws are:
AS 08.80.261 DISCIPLINARY ACTIONS
(a)The board may deny a license to an applicant or, after a hearing, impose a disciplinary sanction authorized under AS 08.01.075 on a person licensed under this chapter when the board finds that the applicant or licensee, as applicable, …
(7) is incapable of engaging in the practice of pharmacy with reasonable skill, competence, and safety for the public because of
(A) professional incompetence; (B) failure to keep informed of or use current professional theories or practices; or (E) other factors determined by the board;
(14) engaged in unprofessional conduct, as defined in regulations of the board.
12 AAC 52.920 DISCIPLINARY GUIDELINES
(a) In addition to acts specified in AS 08.80 or elsewhere in this chapter, each of the following constitutes engaging in unprofessional conduct and is a basis for the imposition of disciplinary sanctions under AS 08.01.075; …
(15) failing to use reasonable knowledge, skills, or judgment in the practice of pharmacy;
(b) The board will, in its discretion, revoke a license if the licensee …
(4) intentionally or negligently engages in conduct that results in a significant risk to the health or safety of a patient or injury to a patient; (5) is professionally incompetent if the incompetence results in a significant risk of injury to a patient.
(c) The board will, in its discretion, suspend a license for up to two years followed by probation of not less than two years if the licensee ...
(2) is professionally incompetent if the incompetence results in the public health, safety, or welfare being placed at risk.
We all acknowledge that Alaska is in the midst of an opioid crisis. While there are published guidelines and literature to assist all healthcare professionals in up to date approaches and recommendations for medical treatments per diagnosis, do not confuse guidelines with law; they are not the same thing.
Pharmacists have an obligation and responsibility under Title 21 Code of Federal Regulations 1306.04(a), and a pharmacist may use professional judgment to refuse filling a prescription. However, how an individual pharmacist approaches that particular situation is unique and can be complex. The Board of Pharmacy does not recommend refusing prescriptions without first trying to resolve your concerns with the prescribing practitioner as the primary member of the healthcare team. Patients may also serve as a basic source of information to understand some aspects of their treatment; do not rule them out in your dialogue.
If in doubt, we always recommend partnering with the prescribing practitioner. We are all licensed healthcare professionals and have a duty to use our knowledge, skill, and judgment to improve patient outcomes and keep them safe.
Professionally,
Richard Holt, BS Pharm, PharmD, MBA Chair, Alaska Board of Pharmacy
https://www.commerce.alaska.gov/web/portals/5/pub/pha_ControlledSubstanceDispensing_2019.01.pdf
FDA in Brief: FDA finalizes new policy to encourage widespread innovation and development of new buprenorphine treatments for opioid use disorder
February 6, 2018
Media Inquiries Michael Felberbaum 240-402-9548
“The opioid crisis has had a tragic impact on individuals, families, and communities throughout the country. We’re in urgent need of new and better treatment options for opioid use disorder. The guidance we’re finalizing today is one of the many steps we’re taking to help advance the development of new treatments for opioid use disorder, and promote novel formulations or delivery mechanisms of existing drugs to better tailor available medicines to individuals’ needs,” said FDA Commissioner Scott Gottlieb, M.D. “Our goal is to advance the development of new and better ways of treating opioid use disorder to help more Americans access successful treatments. Unfortunately, far too few people who are addicted to opioids are offered an adequate chance for treatment that uses medications. In part, this is because private insurance coverage for treatment with medications is often inadequate. Even among those who can access some sort of treatment, it’s often prohibitively difficult to access FDA-approved addiction medications. While states are adopting better coverage owing to new legislation and resources, among public insurance plans there are still a number of states that are not covering all three FDA-approved addiction medications. To support more widespread adoption of medication-assisted treatment, the FDA will also continue to take steps to address the unfortunate stigma that’s sometimes associated with use of these products. It’s part of the FDA’s public health mandate to promote appropriate use of therapies.
Misunderstanding around these products, even among some in the medical and addiction fields, enables stigma to attach to their use. These views can serve to keep patients who are seeking treatment from reaching their goal. That stigma reflects a perspective some have that a patient is still suffering from addiction even when they’re in full recovery, just because they require medication to treat their illness. This owes to a key misunderstanding of the difference between a physical dependence and an addiction. Because of the biology of the human body, everyone who uses a meaningful dose of opioids for a modest length of time develops a physical dependence. This means that there are withdrawal symptoms after the use stops.
A physical dependence to an opioid drug is very different than being addicted to such a medication. Addiction requires the continued use of opioids despite harmful consequences on someone’s life. Addiction involves a psychological preoccupation to obtain and use opioids above and beyond a physical dependence.
But someone who is physically dependent on opioids as a result of the treatment of pain but who is not craving the drugs is not addicted.
The same principle applies to replacement therapy used to treat opioid addiction. Someone who requires long-term treatment for opioid addiction with medications, including those that are partial or complete opioid agonists and can create a physical dependence, isn’t addicted to those medications. With the right treatments coupled to psychosocial support, recovery from opioid addiction is possible. The FDA remains committed to using all of our tools and authorities to help those currently addicted to opioids, while taking steps to prevent new cases of addiction.”
Above is the full statement, find full statement with options for study requests: https://www.fda.gov/NewsEvents/Newsroom/FDAInBrief/ucm630847.htm
Maryland’s co-prescribing new laws/ amendments regarding benzos and opioids
Chapter 215 AN ACT concerning Health Care Providers – Opioid and Benzodiazepine Prescriptions – Discussion of Information Benefits and Risks
FOR the purpose of requiring that certain patients be advised of the benefits and risks associated with the prescription of certain opioids, and benzodiazepines under certain circumstances, providing that a violation of this Act is grounds for disciplinary action by a certain health occupations board; and generally relating to advice regarding benefits and risks associated with opioids and benzodiazepines that are controlled dangerous substances.
Section 1–223 Article – Health Occupations Section 4–315(a)(35), 8–316(a)(36), 14–404(a)(43), and 16–311(a)(8) SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, That the Laws of Maryland read as follows: Article – Health Occupations (a) In this section, “controlled dangerous substance” has the meaning stated in § 5–101 of the Criminal Law Article.
Ch. 215 2018 LAWS OF MARYLAND (B) On treatment for pain, a health care provider, based on the clinical judgment of the health care provider, shall prescribe: (1) The lowest effective dose of an opioid; and (2)A quantity that is no greater than the quantity needed for the expected duration of pain severe enough to require an opioid that is a controlled dangerous substance unless the opioid is prescribed to treat: (a.) A substance–related disorder; (b.) Pain associated with a cancer diagnosis; (c.) Pain experienced while the patient is receiving end–of–life, hospice, or palliative care services; or (d.) Chronic pain
(C.) The dosage, quantity, and duration of an opioid prescribed under [subsection (b)] of this [section] shall be based on an evidence–based clinical guideline for prescribing controlled dangerous substances that is appropriate for: (1.) The health care service delivery setting for the patient; (2.) The type of health care services required by the patient; (3.) and The age and health status of the patient.
(D) (1) WHEN A PATIENT IS PRESCRIBED AN OPIOID UNDER SUBSECTION (B) OF THIS SECTION, THE PATIENT SHALL BE ADVISED OF THE BENEFITS AND RISKS ASSOCIATED WITH THE OPIOID.

 (2) WHEN A PATIENT IS CO–PRESCRIBED A BENZODIAZEPINE WITH AN OPIOID THAT IS PRESCRIBED UNDER SUBSECTION (B) OF THIS SECTION, THE PATIENT SHALL BE ADVISED OF THE BENEFITS AND RISKS ASSOCIATED WITH THE BENZODIAZEPINE AND THE CO–PRESCRIPTION OF THE BENZODIAZEPINE. 

(E) A violation of [subsection (b) OR (D) of] this section is grounds for disciplinary action by the health occupations board that regulates the health care provider who commits the violation.
4-315 (a) Subject to the hearing provisions of § 4–318 of this subtitle, the Board may deny a general license to practice dentistry, a limited license to practice dentistry, or a teacher’s license to practice dentistry to any applicant, reprimand any licensed dentist, place any licensed dentist on probation, or suspend or revoke the license of any licensed dentist, if the applicant or licensee: (35) Fails to comply with § 1–223 of this article.
8–316. (a) Subject to the hearing provisions of § 8–317 of this subtitle, the Board may deny a license or grant a license, including a license subject to a reprimand, probation, or suspension, to any applicant, reprimand any licensee, place any licensee on probation, or suspend or revoke the license of a licensee if the applicant or licensee: (36) Fails to comply with § 1–223 of this article.
14–404. (a) Subject to the hearing provisions of § 14–405 of this subtitle, a disciplinary panel, on the affirmative vote of a majority of the quorum of the disciplinary panel, may reprimand any licensee, place any licensee on probation, or suspend or revoke a license if the licensee: (43) Fails to comply with § 1–223 of this article.
16–311. (a) Subject to the hearing provisions of § 16–313 of this subtitle, the Board, on the affirmative vote of a majority of its members then serving, may deny a license or a limited license to any applicant, reprimand any licensee or holder of a limited license, impose an administrative monetary penalty not exceeding $50,000 on any licensee or holder of a limited license, place any licensee or holder of a limited license on probation, or suspend or revoke a license or a limited license if the applicant, licensee, or holder:
(8) Prescribes or distributes a controlled dangerous substance to any other person in violation of the law, including in violation of § 1–223 of this article;
SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect October 1, 2018.
Approved by the Governor, April 24, 2018.
https://legiscan.com/MD/text/HB653/id/1788719/Maryland-2018-HB653-Chaptered.pdf

​
Heimplanet Transit Sling Pocket 2L
I was inundated with 1s and 2s of requests clamoring for me to expound a bit more on this sling bag in response to my updated packing list. This isn't a review so much as a look at why it's a dope-ass bag for my specific use cases, as well as how I've decided to pack it out after 3 years of use.
I sprung for a sling bag/fanny pack/bum bag in order to solve a few problems:

• Avoid having to remove my main pack to get to specific items
• Maintain quick access to my most commonly-used items
• Keep things out of trouser pockets

After demoing ten sling bags in my home during the pandemic, I landed on the Heimplanet Transit Sling Pocket 2L based on its sleek appearance, reasonable capacity, and excellent quality and craftsmanship. (I also took a look at the XL version but passed on it because I had just downsized from the Farpoint 55 to the Osprey Nebula 34L to test drive for a couple of weeks in Colorado, and I didn't want to go bigger for fear of just filling the sling with my crap I didn't need.)
So, on that note, here are my sling bag essentials:
Loadout

• Wallet
• Passport
• Wireless Bluetooth Earbuds
• Sunglasses
• Eyeglasses
• Noise filters
• Lip balm
• Toothpicks
• Hand cream
• Ibuprofen
• Mints
• Mobile device

Let's start with arguably my favorite feature of the bag: The front pocket.
Front pocket
Doesn't look that big, right? It looks like there would only enough room for a pair of glasses as designed.
Front pocket w/ glasses
Upon further inspection, however...
Front pocket w/ glasses AND earbuds case
...it turns out you can fit a deceiving amount of things here, including giant-ass earbuds cases like the Beats Fit Pro.
The reason this was a game-changer for me is because I used to keep my Jabra Elite 75t earbuds in one of the elastic pockets in the main compartment. However, in the back of a cab one day in Oaxaca, I happened to not zip up my sling all the way (which you'll find is a recurring theme in this post) and I'm sure it flung out at some point. (Luckily, as noted with some other items I lost or damaged on my travels in my packing list update, Amex Platimum's protection benefits helped me replace the Jabras with the Beats Fit Pro.) The fit with glasses is snug, but not too tight, and there is no threat of it falling out, even if you don't zip up the front pocket. Now, I just jam my earbuds here every time and I haven't had an incident since.
The other slick thing about this setup is that my two most important pieces of tech--my smartphone and my earbuds--have their own dedicated locations in the bag. There's always going to be a small amount of risk of loss (or theft) every time I have to unzip the main compartment and get into it, so anything that limits my main compartment access attempts and directs my activity elsewhere in the bag is a good thing.
(Of course, if you're not occasionally careless like me, this is a non-issue.)
What the front looks with the glasses + earbuds case
The bulge isn't nearly as pronounced when unassisted by my fingers
Moving on, here's what the main compartment looks like when it's loaded out:
The goodies
Smushed together view for better view of the elastic side pockets
Please note that, most of the time, my passport stays put in the Zero Grid holder in the quick access pocket of my Patagonia Cragsmith 32L when not in use. I only travel with my passport in my sling while I'm in transit to somewhere where passport verification is required. The zippered pocket in the main compartment does not fit the Zero Grid Passport Holder, but I am not in the least bothered by this because it's one less thing I have to fuss about with when I'm quickly whipping out my passport at the airport.
Here's where my Google Pixel 7 Pro goes:
https://preview.redd.it/7tri2zkmuq3b1.jpg?width=4048&format=pjpg&auto=webp&s=37db1577c33edad704262ac2a1fa5e4bf0fbfd91
https://preview.redd.it/vqbxqastuq3b1.jpg?width=4048&format=pjpg&auto=webp&s=1479444ba6017ed7af394cbfd375fe00a7d03254
Quick aside: As mentioned in the previous post, I had a Pixel 6 Pro that I broke in Uruguay. I was leaving my host's flat in Punta del Este waiting for the elevator. I had my back turned, and when it opened, I put my phone in my sling and turned around quickly to enter the elevator. The phone flung completely out of my bag and landed screen first on the tile floor. I had a Spigen case on it with screen protector, but I had a bad habit of dropping the phone almost daily anyway, so the resultant 95% black screen was really only a matter of time. Note to the lazy: Please don't be like me, zip up your bag.
As a result of this carelessness, I picked up a lanyard for my new Pixel 7 Pro and Spigen case, and I happened to stumble upon another layer of security to guard against this in the future: Connecting the lanyard to a carabiner I affixed to the front loop of the bag.
Phone lanyard + caribiner attached to front loop
This has actually been quite a cool feature for me the last couple of months:

• I can still zip up the bag
• I can visually verify that I have my phone without getting into the main compartment
• There's enough slack where I can quickly review walking or public transit instructions without disconnecting the lanyard from the carabiner

Here's the sling bag completely packed out:
Loaded out - top view
Loaded out - side view
Finally, let's look at the nylon straps:
Nylon strap - rear view
HPT = high pressure torsion, aka tough af
As you can see, there's a small gap in the hardware that connects the strap to the bag for ease of replacement and/or cleaning of the bag or strap.
Now that I've covered the lanyard + carabiner combo and strap, let's get into my click-baity title: How I was mugged in the Dominican Republic.
Before the inevitable victim-blaming comments pour in, I will admit that I put myself in a non-ideal situation. Of course, I know I didn't deserve it (no one does), but in hindsight there were a few mitigating steps I could have taken to minimize risk.
The story: I'm sitting at a bus stop alone on a busy street with one else around with my sling bag, Cragsmith, and earbuds in, trying to get back to my friend's flat. The sun is setting so it wasn't quite nightfall, but dark enough. I notice two guys walk by and cross the street. They look right at me, and then one of them at my phone. I promptly put my phone away, which is attached to the carabiner on the sling. Multiple vehicles, including three police trucks, drive by in a 5-min span. I checked my surroundings before I took out my phone again to double check bus ETA.
When I look up again, the same two guys suddenly reappear and are briskly walking across the straight right toward me. They aren't visibly armed with any weapons, but what is going to unfold is not left to question. I start shouting and cursing them out in Spanish to draw as much attention as possible as one guy lunges at me and grabs my phone and hoodie, while the other guy goes for my sling bag.
I hold onto everything as they drag me off the bus stop bench. I hit the back of my head on the bench on the way down and I was on my back. The guy on my phone almost rips my hoodie clean off but he can't dislodge my phone from my hand. He lets go of the phone and just focuses on my hoodie instead for some reason. The other guy is violently and furiously yanking on my sling bag, but it just will not break. I reach for my Hydroflask bottle out of my Cragsmith and whip it against the knees of one guy twice, and I start Spartan-kicking the other guy in the balls while still on my back. After what seems like an eternity, both guys seem to give up and let go. I take this chance to get up and I started swinging my water bottle + paracord sling wildly.
They finally run away when a taxi driver stops to help me out.
So, yeah. That happened. I was rattled for several days afterward, and it really impacted my ability to enjoy Puerto Rico the following week after arriving from DR. Lots of lessons learned, and I hope I never find myself in that situation ever again.
To bring the focus back to the sling bag, I reviewed its condition thoroughly when I finally got back to my friend's place. There was no indication that it had been in a struggle, and no sign of fraying, tearing, or damage to either the nylon strap, the loops that they connect to, or the aluminum hardware. As I said, the one guy was hellbent on ripping the bag off of me with several deliberate, measured pulls, as if he were taking deep breaths each time. He was pulling so hard, I ended up with strap burns and accompanying pain around my neck and under my left arm, neither of which I noticed until an hour after the assault.
This bag is amazing, 10/10, would recommend, everyone go get one.
And more importantly, I am super lucky it didn't end up worse. Thank god they weren't armed.
To lighten the mood, here's my real favorite feature of the bag: Personalizing it with an elephant charm I bought from a homeless guy in the US before I took off on my trip.
(I broke the elephant trunk moshing near the Obelisk in Buenos Aires while celebrating Argentina's World Cup quarterfinals win. Obviously worth it 🥳)
At this point it's obvious that I love this sling bag with all of my heart. On a normal day--especially with my new security best practices--I'm in and out of this bag, zipping and unzipping, likely a legit 100 times. It is built to withstand a staggering amount of abuse while looking super fly, and its utility is endless. This is, without a doubt, the most crucial purchase I've made to my onegear kit.

Social media have become an integral part of our lives, offering not only entertainment and communication, but also new opportunities for businesses. In this context, Instagram and TikTok stand out particularly brightly. Their popularity and influence in the world of social media are steadily growing, and influencers on these platforms are becoming a force capable of shaping public opinion and exerting a significant influence on consumer behavior.
https://preview.redd.it/3i1rdo89jm3b1.jpg?width=1920&format=pjpg&auto=webp&s=4b718bab3245b6f6b96f192ff249282ff31ee261
Cooperating with influencers on Instagram and TikTok is an effective marketing tool for gambling projects. Examples of successful collaborations between bloggers and gambling projects on Instagram and TikTok are impressive and demonstrate the potential of this type of marketing. Bloggers often create interesting and appealing content that integrates gambling projects into their regular posts. They can share their winnings, game strategies, or simply talk about their gambling experiences. This allows iGaming projects to reach a wide audience that may be interested in such forms of entertainment.
It is worth noting the presence of a negative audience on social media, especially on TikTok. Encountering hate and negative comments on this platform can be the easiest. That is why selecting the right influencers with a warm and receptive audience who have a positive attitude towards gambling advertising is an important task. In the face of a vast number of influencers on TikTok and Instagram, we have prepared 2 researches:

1. Gambling/iGaming Instagram Inventory List for Marketing 2023
2. Gambling/iGaming TikTok Inventory List for Marketing 2023

We have collected 3 438 influencers ready to promote gambling. Based on this data, let's make the top 50 influencers on Instagram and TikTok.

idx	Name	Platform	Followers
1	barstoolsports	TikTok	27 300 000
2	bleacherreport	Instagram	20 917 830
3	funnyhoodvidz	Instagram	17 069 181
4	egorkreed	Instagram	14 665 056
5	egorkreed	TikTok	12 500 000
6	loud_victor	Instagram	11 184 367
7	loud_coringa	TikTok	8 800 000
8	evtushenko_dima	TikTok	7 900 000
9	mrstiventc1977	TikTok	7 200 000
10	ziilverk	TikTok	7 200 000
11	jonvlogs	Instagram	6 406 242
12	rodrigofee2	Instagram	4 772 613
13	ivanzolo2004	TikTok	3 800 000
14	bruninzor	TikTok	3 700 000
15	elgato	TikTok	3 600 000
16	piuzinholl	Instagram	3 512 900
17	jonvlogs	TikTok	3 300 000
18	lasapaaaaa	TikTok	2 800 000
19	stiven.tc	Instagram	2 780 613
20	dilbliin	TikTok	2 200 000
21	bingojunkiess	TikTok	2 200 000
22	evelone1922	TikTok	2 100 000
23	slaterkodish	TikTok	2 000 000
24	rachaxp	Instagram	1 966 935
25	fluxo_two9	Instagram	1 918 052
26	evtushenko_dima	Instagram	1 797 746
27	alanafloresf	TikTok	1 700 000
28	tima_maconi	TikTok	1 700 000
29	kyivstoner	Instagram	1 663 612
30	paradeevich	TikTok	1 600 000
31	diegoneira3	TikTok	1 500 000
32	eypiedra	TikTok	1 500 000
33	lopezzjoacoo	Instagram	1 456 272
34	thenotoriousprankedy	Instagram	1 430 137
35	kareykadasha	Instagram	1 339 234
36	elranty	Instagram	1 301 162
37	westcol	Instagram	1 269 735
38	calaaaango	Instagram	1 240 844
39	davoobj	Instagram	1 184 008
40	gazzettadellosport	Instagram	1 130 765
41	fluxo_gorilatv	Instagram	1 111 213
42	davooxeneize	TikTok	1 100 000
43	gensyxa	TikTok	1 100 000
44	sport1news	TikTok	1 100 000
45	neekolul	TikTok	1 100 000
46	linfnx	Instagram	1 052 693
47	nsmartynov	Instagram	1 049 458
48	sharkao	Instagram	1 047 934
49	dedeof	Instagram	1 001 195
50	el_ranty	TikTok	1 000 000

According to the selection above, there are:

• 17 influencers with over than 3 000 000 followers
• 33 influencers with less than 3 000 000 followers

Advantages

Collaborating with influencers on these platforms offers several advantages for gambling projects:

1. Wide audience.

Instagram and TikTok bloggers have a huge subscriber base, allowing for reaching a broad range of users and brand recognition. 214,269,797 people follow the listed 50 accounts.

1. Influence and trust.

Followers trust influencers and follow their advice and recommendations. Collaborating with bloggers allows gambling projects to leverage this trust and convince users to try their services.

1. Creative content.

Original content attracts new subscribers and retains existing ones. Through collaboration with influencers, iGaming projects can create content that captures the audience's attention and sparks their curiosity about the product.

1. Unique advertising formats.

Instagram and TikTok offer diverse advertising formats that can be effectively utilized by gambling businesses, from direct advertising posts to guerrilla marketing. The format of short videos ranging from 15 to 60 seconds enables reaching a vast audience, as there is a high likelihood of creating viral videos, which can be viewed by tens or hundreds of millions of people.
All of the above accounts are great for advertising iGaming. Let's look at the most popular accounts on TikTok and Instagram.

barstoolsports

Platform: TikTok
Followers: 27 300 000
Optimal for: All thing gambling
Barstool Sports is a popular sports and pop culture media company that was founded by Dave Portnoy in 2003. It started as a print publication in Boston and has since grown into a multi-platform digital media empire with a significant online presence. Barstool Sports has gained a large following due to its unique and often irreverent approach to covering sports and entertainment.
The company covers a wide range of topics including professional and college sports, gambling, viral videos, and celebrity gossip. Barstool Sports push the boundaries of traditional sports journalism and aren't afraid to take risks or tackle sensitive subjects.
They have a strong presence on social media platforms like Tik Tok, where they share a condensed and dynamic version of their content. On their TikTok account, Barstool Sports offers a mix of sports-related videos, humorous skits, and viral clips. There are 27 300 000 potential customers who are positive about advertising gambling products.

bleacherreport

Platform: Instagram
Followers: 20 917 830
Optimal for: Projects related to sports
Bleacher Report (BR) is a popular media portal specializing in sports journalism, news, analysis, and entertainment. It was founded in 2007 and has since become one of the leading sports websites in the world. One of the key features of Bleacher Report is its team of authors and journalists. Over 2 000 experts and writers collaborate with BR, offering their unique perspectives and analysis of sports events.
The official Instagram account of Bleacher Report (BR) is one of the most popular and influential sports accounts on social media. Since its creation, it has gathered a huge audience of sports fans and offers engaging content related to sports news, game highlights, interviews, entertainment, and much more.
This account has amassed over 20 000 000 sports enthusiasts. The account can be an excellent tool for promoting a bookmaking company as it averages 3 000 000 views on Reels. And this is not the only advertising method available, you can also buy ads in Stories, posts, or live broadcasts.

funnyhoodvidz

Platform: Instagram
Followers: 17 069 181
Optimal for: All thing gambling
The Instagram account u/funnyhoodvidz is a platform dedicated to humorous content. Through it, users can enjoy a wide variety of funny videos, hilarious pictures, and memes.
The account page is highly popular among Instagram users as it offers entertaining content. As for advertising, you may come across advertisements for gambling games on the profile. For example, you can purchase a series of posts and stories, just like Stake did. They regularly appear in the account's stories throughout the year.

egorkreed

Platforms: TikTok, Instagram
Followers: on Instagram -14 665 056; on TikTok - 12 500 000
Optimal for: All thing gambling
egorkreed, whose real name is Yegor Bulatkin, is a popular Russian singer. He has a large number of followers on social media and actively engages with his fans on Instagram, TikTok, YouTube, and Twitch. The singer promotes various products, ranging from video games to online casinos.
egorkreed holds an impressive position in our ranking, with a combined total of 27 165 056 followers on both social media.
https://preview.redd.it/30nto1ycjm3b1.jpg?width=1920&format=pjpg&auto=webp&s=05bc44f44d069ca7a8f5337c8f0fd1998b8b9d3e

The power of social media

The power of social media for businesses lies in its ability to significantly increase brand awareness and facilitate direct communication with customers, enabling companies to reach a large audience, engage in real-time conversations, receive feedback, address inquiries or concerns, build trust, enhance customer loyalty, and cultivate a positive brand image.
Instagram and TikTok belong to the best social media to promote gambling. The various formats of influencer advertising available on these platforms provide gambling projects with unique opportunities to engage their audience and increase brand visibility. Sponsored posts, partnership contests and giveaways, video reviews and recommendations, as well as live streams - all these formats allow projects to be presented in a creative and appealing way. Instagram and TikTok influencers have the ability to create original content, interact with their audience, and share their impressions, strategies, and advice with them.

I see these ponds near where we will be staying, particularly the golf course. Wondered if they were “fishable” and if they stock bass like in southern USA?

https://preview.redd.it/1asb17tlye3b1.png?width=3500&format=png&auto=webp&s=d5e767b6f1a867be0ca5dbc5e9f388b294800a0d
(TheNewswire)
https://preview.redd.it/6afwxvvlye3b1.png?width=720&format=png&auto=webp&s=ab9327bf0ca7c12bfb1c82c572bd20f8c868de4a

Toronto, ON

TheNewswire

• June 1, 2023 - AbraSilver Resource Corp. (TSX.V:ABRA ) ( OTC:ABBRF) (“AbraSilver” or the “Company”) is pleased to report positive preliminary metallurgical test results for the new JAC zone at its wholly-owned Diablillos property in Salta Province, Argentina (“Diablillos” or the “Project”). The program was completed by independent metallurgical consultants, SGS Canada Inc., at their testing facilities in Lakefield, Ontario.

Key Highlights Include:

• Overall recoveries at the JAC and Fantasma deposits range between 86% - 93% for silver and 82% - 91% for gold.
• A substantial percentage of the silver at JAC can be recovered by gravity separation which increases overall recoveries.
• Current testwork confirms that the same process flowsheet can be used to process mineralization from the Oculto, JAC and Fantasma deposits.
• Milling tests have shown that 150 microns is the targeted grind size for the leaching of the mineralized material at a retention time of 36 hours.
• Overall silver and gold recoveries could likely be increased further by grinding finer and with higher cyanide concentrations. Further metallurgical testwork and trade-off studies are now underway.

John Miniotis, President and CEO, commented, “We are extremely pleased that the metallurgical testwork results at JAC demonstrate excellent recovery rates for both silver and gold. These results show that mineralization at JAC responds very well to conventional processing and recovery technologies, providing highly positive implications for the future development potential of the project. The results will be incorporated into our Mineral Resource estimate and Pre-Feasibility Study which remain on track to be delivered later this year.”
Favorable Recovery Rates vs. Prior Testwork
At the JAC and Fantasma deposits the silver minerals (chlorargyrite and iodargyrite) are easier to release by grinding, and are more sensitive to cyanide leaching as they occur in argillic alteration , whereas at Oculto they are mostly held more complexly in vuggy silica host rock.
Table 1 - Summary of Metallurgical Testwork Results for JAC and Fantasma Deposits
Processing img z0i7lpwlye3b1...
Click Image To View Full Size
Testwork on JAC and Fantasma samples showed that gravity separation before cyanide leaching recovers approximately 9% of the silver and 17% of the gold
which, when combined with the subsequent cyanide leaching recoveries, results in total overall recoveries of between 86% and 93% for silver and between 82% and 91% for gold.
Table 2 below shows gravity plus cyanide leach recoveries at the JAC and Fantasma deposits compared with the Oculto deposit recoveries announced in the PEA announced in January 2022.
Table 2 – Latest Metallurgical Testwork Results vs. Jan. 2022 PEA Study
Processing img 8ymvqiylye3b1...
Click Image To View Full Size
1 Recovery rates for Oculto PEA reflect the life of mine average as per the report published on Jan. 13, 2022 titled “NI 43-101 Preliminary Economic Assessment Technical Report – Diablillos Project”
A median of 89.5% recoveries for silver and 86.5% for gold at JAC and Fantasma compare favourably against the 73.5% silver recoveries and 86.0% gold recoveries used for the Preliminary Economic Assessment (“PEA”) at Oculto. The median silver recovery of 89.5% relative to 73.5% for Oculto is particularly relevant because the mineralization at the JAC and Fantasma deposits is predominantly silver.
Figure 1 – Median Recoveries at the JAC & Fantasma Deposits Compared with the Oculto Deposit
https://preview.redd.it/y433zczlye3b1.png?width=608&format=png&auto=webp&s=77c219ad858889d07a676f838ff176ad495f2643
JAC drill core samples for metallurgical testing were selected to be volumetrically representative of the mineralised system, being from the various zones of mineralisation along strike and at depth, including high, medium and lower grades. Care was taken not to mix alteration zones so that geo-metallurgical domains can be determined.
Additional metallurgical testing is being conducted on samples from different geo-metallurgical domains at Oculto in an effort to boost overall recoveries, especially from areas with high silver grades.
Metallurgical Test Program Overview
This campaign was the first metallurgical testwork program conducted on the new JAC zone, discovered in August 2022, and on the already known Fantasma deposit. W ork completed involved comminution, gravity, leaching and thickening testwork of fourteen variability composites with twelve from the JAC zone and two from the Fantasma zone. The results will be incorporated in the upcoming Mineral Resource estimate (“MRE”) update and Pre-Feasibility Study (“PFS”) for the overall Diablillos project.
The results confirm that the Diablillos project will have a conventional silvegold processing plant flowsheet incorporating crushing, grinding, gravity concentration and intense cyanidation circuit, cyanide leaching with oxygen addition, counter current decantation (“CCD”) washing thickeners and Merrill-Crowe precious metal recovery from solution followed by on-site smelting to doré bars.
A summary of the processing flow sheet for the Diablillos project is shown below.
Figure 2 – Simplified Process Flowsheet for the Diablillos Project
https://preview.redd.it/nwvyke0mye3b1.png?width=800&format=png&auto=webp&s=1bc78e911e461bafcc66218848e196922d8242d9

• Bulk mineralogical investigation determined that quartz, alunite, and iron-oxides were the major mineral components of the samples, and it is demonstrated that most of the silver will respond well to direct cyanidation. The JAC composite was used for most of the testing program, with average head grades of 0.11 g/t gold and 148 g/t silver.
• Response to standard gravity separation tests for the recovery of free silver and gold resulted in average recoveries of 9% and 17%, respectively. As a result, the overall gravity plus cyanidation recoveries achieved were 86% to 93% for silver and 82% to 91% for gold
• The following optimum whole ore cyanidation conditions were established for the JAC composite and applied to the variability samples:

• Grind size P80 of 150 μm,
• 45% pulp density (w/w),
• pH of 10.5-11.0 (maintained with lime),
• 4 hours of pre-aeration with air sparging,
• air-sparging during leaching,
• Sodium cyanide (NaCN) concentration of 1.5 g/l maintained for the first 12 hours of leaching and then allowed to naturally decay for the remaining leach time.

• The testwork showed that silver and gold recoveries could likely be further increased by grinding finer (P80 of 70 μm versus 150 μm) and by increasing cyanide consumption from 1.5 g/l to 2.5 g/l. Further metallurgical testwork and trade-off studies will be conducted to confirm the optimum process route.
• Environmental assessment of the leach tailings samples showed the potential for acid generation in some samples. On-site humid cell testwork is planned and mitigating measures will be designed as part of the tailings management strategy.
• Settling/thickening and rheology tests were performed on the JAC composite cyanide leach and cyanide destruction residue, showing a fast-settling rate in response to tested flocculants. Counter Current Decantation (CCD) modelling was performed as well, resulting in a 4 stages CCD circuit producing a final wash efficiency of 99.8%

Future Work Programs

• Cyanide leach tests will continue on the samples from Oculto, JAC and Fantasma to optimize recovery and leach time. Drivers to improve recoveries will include stronger cyanide solutions, grind size of the ore, and leaching residence times.
• As gravity separation was successful in concentrating gold and silver at the JAC deposit, it is proposed that additional testing of gravity separation in advance of cyanidation be carried out on mineralisation types at Oculto, where there are both gold and silver dominant geo-metallurgical zones.
• At the Diablillos site, humid cell test work is ongoing to evaluate acid rock drainage generation from the cyanidation tailings under site conditions to support potential mitigating measures in the tailings management strategy.
• Heap leaching test work will be conducted to investigate the possibility of recovering lower grade material.

About Diablillos
The 80 km 2 Diablillos property is located in the Argentine Puna region - the southern extension of the Altiplano of southern Peru, Bolivia, and northern Chile - and was acquired from SSR Mining Inc. by the Company in 2016. There are several known mineral zones on the Diablillos property, with the Oculto zone being the most advanced with over 120,000 metres drilled to date. Oculto is a high-sulphidation epithermal silver-gold deposit derived from remnant hot springs activity following Tertiarty-age local magmatic and volcanic activity. Comparatively nearby examples of high sulphidation epithermal deposits include: Yanacocha (Peru); El Indio (Chile); Lagunas Nortes/Alto Chicama (Peru) Veladero (Argentina); and Filo del Sol (Argentina).
The most recent Mineral Resource estimate for the Oculto Deposit is shown in Table 3:
Table 3 - Oculto Mineral Resource Estimate – As of October 31, 2022
Processing img 55hvtb1mye3b1...
Click Image To View Full Size
Notes: Effective October 31, 2022. Mineral Resources are not Mineral Reserves and have not demonstrated economic viability. The Mineral Resource estimate is N.I. 43-101 compliant and was prepared by Luis Rodrigo Peralta, B.Sc., FAusIMM CP(Geo), Independent Consultant. The mineralization estimated in the Mineral Resource is sub-horizontal with sub-vertical feeders and a reasonable prospect for eventual economic extraction by open pit methods. For additional information please see Technical Report on the Diablillos Project, Salta Province, Argentina, dated November 28, 2022, completed by Mining Plus, and available on www.SEDAR.com.
QA/QC and Core Sampling Protocols
AbraSilver applies industry standard exploration methodologies and techniques, and all drill core samples are collected under the supervision of the Company’s geologists in accordance with industry practices. Drill core is transported from the drill platform to the logging facility where drill data is compared and verified with the core in the trays. Thereafter, it is logged, photographed, and split by diamond saw prior to being sampled. Samples are then bagged, and quality control materials are inserted at regular intervals; these include blanks and certified reference materials as well as duplicate core samples which are collected in order to measure sample representivity. Groups of samples are then placed in large bags which are sealed with numbered tags in order to maintain a chain-of-custody during the transport of the samples from the project site to the laboratory.
All samples are received by the SGS offices in Salta who then dispatch the samples to the SGS preparation facility in San Juan. From there, the prepared samples are sent to the SGS laboratory in Lima, Peru where they are analyzed. All samples are analyzed using a multi-element technique consisting of a four-acid digestion followed by ICP/AES detection, and gold is analyzed by 30g Fire Assay with an AAS finish. Silver results greater than 100g/t are reanalyzed using four acid digestion with an ore grade AAS finish. Analytical results are statistically processed for final acceptance.
Qualified Persons
David O’Connor P.Geo., Chief Geologist for AbraSilver, is the Qualified Person as defined by National Instrument 43-101 Standards of Disclosure for Mineral Projects, and he has reviewed and approved the scientific and technical information in this news release.
About AbraSilver
AbraSilver is an advanced-stage exploration company focused on rapidly advancing its 100%-owned Diablillos silver-gold project in the mining-friendly Salta province of Argentina. The current Measured and Indicated Mineral Resource estimate for Diablillos consists of 51.3 Mt grading 66g/t Ag and 0.79g/t Au, containing approximately 109Moz silver and 1.3Moz gold, with significant further upside potential based on recent exploration drilling. The Company is led by an experienced management team and has long-term supportive shareholders including Mr. Eric Sprott. In addition, AbraSilver owns a portfolio of earlier-stage copper-gold projects including the La Coipita copper-gold project in the San Juan province of Argentina. AbraSilver is listed on the TSX-V under the symbol “ABRA” and in the U.S. under the symbol “ABBRF”.
For further information please visit the AbraSilver Resource website at www.abrasilver.com , our LinkedIn page at , and follow us on Twitter at
Alternatively please contact:
John Miniotis, President and CEO
[[email protected]](mailto:[email protected])
Tel: +1 416-306-8334
Cautionary Statements
This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. All statements that address future plans, activities, events or developments that the Company believes, expects or anticipates will or may occur are forward-looking information. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. When considering this forward-looking information, readers should keep in mind the risk factors and other cautionary statements in the Company’s disclosure documents filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in the disclosure documents could cause actual events or results to differ materially from those described in any forward-looking information. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release
Copyright (c) 2023 TheNewswire - All rights reserved.
https://preview.redd.it/c4whc92mye3b1.png?width=4000&format=png&auto=webp&s=4ff64cc5a4ddda8a9d901c1b9b4ec76d57af5356

Universal Site Links
ABRASILVER RESOURCE CORP
STOCK METAL DATABASE
ADD TICKER TO THE DATABASE
www.reddit.com/Treaty_Creek
REPORT AN ERROR

¡Buenas! Las cosas son de mi suegra que está haciendo una venta de garaje por mudanza y se retiran en Floresta, yo solo le doy una mano publicando las cosas porque no usa redes.

Si te interesa algo, escribime y te paso su contacto por privado y cerrás la operación con ella.

Además estoy vendiendo cosas mías también, las cuales se prueban y retiran en mi domicilio en Lanús oeste; Las cosas mías comienza al final de las de mi suegra.

Los precios de mis artículos se pueden negociar, los de mi suegra se arreglan con ella.

Pase y vea...

________________________________________________________________________________________________________________
Los artículos de mi suegri:
​
Cama cucheta triple con cajonera y escalera (no incluye colchones)

🟢 Diseñada de madera aglomerada recubierta en melamina. Cuenta con una repisa para la cama de abajo, una pequeña puerta y un cajón.

MEDIDAS:

↔️ Ancho: 230Cm

↕️ Alto: 154Cm

↙️ Profundidad: 89Cm

⚖️Peso: 112Kg

🟢 Se encuentra en impecable estado, menos de un año de uso cuidado. ¡No incluye colchones!

💲PRECIO: 65K

MÁS FOTOS DE LA CAMA ACÁ

________________________________________________________________________________________________________________
Aire Acondicionado Portátil Sansei SAP35HC2AD

🟢 Aire acondicionado Sansei modelo SAP35HC2AD en perfectas condiciones. Es primera mano. Fue comprado nuevo y se le dio 1 año y medio de uso moderado en una habitación pequeña, por lo cual el artefacto no tuvo uso forzado.

✅ Función sueño: Sí

✅ Función deshumidificación: Sí

✅ Función Frío: 3010 frigorías - 3500 W

✅ Función Calor: 2650 W

✅ Función ventilación: Sí

✅ Con temporizador: Sí

✅ Incluye control remoto: Sí

💲PRECIO: 95K

MÁS FOTOS DEL AIRE ACÁ

__________________________________________________________________

Licuadora con molinillo Liliana

Art. AL 503 de Liliana.

La jarra de la licuadora se rompió, por lo que solo se entrega con el molinillo. Se consigue el repuesto de la jarra.

💲PRECIO: 3K

MÁS FOTOS DE LILIANA ACÁ

__________________________________________________________________

Artículos tech míos:
​
Tableta Gráfica Huion Kamvas 13 Pen Display

FOTOS: Tableta Gráfica Pen Display Huion Kamvas 13

💲PRECIO: 120k - 5% OFF pagando en btc/crypto

DESCRIPCIÓN: Kamvas 13 purple prácticamente nueva, no tiene ningún detalle estético ni técnico, inclusive no se le llegó a quitar el film protector.

Se entrega con todos los accesorios originales, inclusive todas las puntas del lápiz ya que no se gastó ni una.

__________________________________________________________________

​
​
Notebook HP Probook 640 G1

FOTOS: Notebook HP Probook 640 G1

💲PRECIO: 82k - 5% OFF pagando en btc/crypto

DESCRIPCIÓN: Tiene 8gb de ram ddr3 (expandible a 16gb). Cuenta con un procesador I5 4200m con gráficos HD Intel 4600, batería funcional.

La usaba para editar giladas en Photoshop, videítos en Premiere Pro y producir música en Fl Studio y Protools.

Almacenamiento: Disco sólido 120gb Gigabyte.

Algunas características de la máquina: wifi, bluetooth, 4 puertos usb, lectrograbadora de dvd, lector de tarjetas sd, in/out de auriculares/micrófono y salida de video vga/display port. Por dp/hdmi soporta resoluciones 4k, por vga 3k.

Se entrega con su fuente original.

________________________________________________________________________________________________________
Notebook HP Probook 440 G5

FOTOS: Notebook HP Probook 440 G5

💲PRECIO: 158k - 5% OFF pagando en btc/crypto

DESCRIPCIÓN: Tiene 8gb de ram (expandible a 32gb). Cuenta con un procesador I5 8250u (4 núcleos y 8 hilos) con gráfica dedicada Intel UHD Graphics 620La batería está en estado aceptable.

Algunas características de la máquina: Wifi, bluetooth, 2 puertos usb 3.1, puerto usb tipo C 3.1, lector de tarjetas sd, in/out de auriculares/micrófono y salida de video hdmi/vga.

Destaco muchísimo el sonido que tiene esta máquina, suena muy fuerte y la calidad del micrófono es muy buena también, ideal para ver pelis o trabajar con audio.

Se entrega con su fuente original.

__________________________________________________________________

Notebook Lenovo Thinkpad T460
​

FOTOS: Notebook Lenovo Thinkpad T460

💲PRECIO: 155k - 5% OFF pagando en btc/crypto

DESCRIPCIÓN: Tiene 8gb de ram (expandible a 32gb).

Cuenta con dos baterías, la externa dura mas de 6hs en iddle y la interna está prácticamente nueva, dando autonomía durante todo el día sin problemas.

Cuenta con un procesador I5 6300u Intel HD Graphics 520.

Almacenamiento: Disco sólido SSD msata 256gb Samsung de alta velocidad!

Algunas características de la máquina: Wifi, bluetooth, 3 puertos usb 3.1, puerto usb tipo C 3.1, lector de tarjetas sd, in/out de auriculares/micrófono y salida de video hdmi/vga/mini display port.

Se entrega con su fuente original.

________________________________________________________________________________________________________
Artículos musicales míos:
​
Guitarra Stratocaster Washburn Pro Lyon Series

FOTOS: Guitarra Stratocaster Washburn Pro Lyon Series

💲PRECIO: 96k - 5% OFF pagando en crypto

DESCRIPCIÓN: El color es un verde petróleo metálico. La guitarra tiene un killswitch mod con un botón de arcade que se puede apreciar en las imágenes. Lo mandé a hacer con un luthier de confianza, le hizo la jaula de faraday al circuito y algunos ajustes a mi gusto como sacarle 2 de los resortes del puente. También la mandé a calibrar y hacerle la rectificación de trastes por el mismo luthier.

Va con un encordado sellado Ernie Ball 0.09, correa, cable y slide.

________________________________________________________________________________________________________
​
Compresor de Audio Boss Pro CL50

FOTOS: Compresor de Audio Boss Pro CL50

💲PRECIO: 88k - 10% OFF pagando en crypto

DESCRIPCIÓN:

• Compresor, limitador y puerta de ruido. Ideal para, nivelar o limitar los picos de señal a la entrada o final de la cadena de efectos o de la mesa de mezcla.• Tiene entrada "Detector In", para usar como compresión en paralelo (side-chain), esto sirve para que el compresor se active solo cuando llega señal por el Detector In.• También tiene entrada de footswitch, Comp Remote, para ponerle un pedal y controlar el on/off en vivo con tu instrumento, por ejemplo en tu cadena de efectos de guitarra. O simplemente para tener un mayor dominio del compresor en tu estudio.• Stereo Link para poner efectos en serie• Level (dBm), para seleccionar entre 2 circuitos de entrada con diferente resistencia.

Se dice del CL 50 que es un Dbx 160x con licencia de Boss, comparten prácticamente todos los componentes y hay muchas similitudes en el circuito, pero el CL 50 cuesta 3 veces menos, teniendo en cuenta que el chasis es mucho mas pequeño que el Dbx 160x. Además ambos se fabricaron en Japón.

Se entrega con transformador.

________________________________________________________________________________________________________
Banjo Epiphone MB-100

FOTOS: Banjo Epiphone MB-100

💲PRECIO: 250k - 5% OFF pagando en crypto

DESCRIPCIÓN: Banjo es de 5 cuerdas, parche remo openback.Incluye correa, llave hexagonal (para cambiar o afinar el parche), afinador digital de clip (para ponerlo en la pala del banjo), encordado Ernie Ball (de las mejores cuerdas) y uñeros.

El estuche rígido es un Road Runner (de los mejores hardcases), el mismo es opcional y se suma un valor adicional si lo querés.

__________________________________________________________________

Teclado Sintetizador Yamaha DJX PSR-D1

FOTOS: Teclado Sintetizador Yamaha DJX PSR-D1

💲PRECIO: 180k - 10% OFF pagando en crypto

DESCRIPCIÓN: El teclado funciona de 10, no tienen ninguna falla técnica. Estéticamente tiene esa quemadura que sucedió por un accidente a causa de un músico muy falopeado y un cigarro. Lo que se puede hacer con este teclado lo podés ver en reviews de Youtube, es una locura ya que es un teclado sintetizador, tiene efectos y sonidos programables, podés hacer split, samplear con sonidos externos, grabar, etc... creo que tengo el manual inclusive por ahí.

Se entrega con transformador y un pedal de sustain!

__________________________________________________________________

💲¿MÉTODOS DE PAGO?: Se acepta Crypto/Wise/ARS tx/ARS Efvo -

Para los artículos de mi suegra si tenés crypto* y no querés andar haciendo malabares, te puedo facilitar la transacción yo porque ella no usa y luego arreglo con ella.

Wise y pesos argentinos podés hacerlo tranquilamente con ella.

📦 ¿ENVÍOS?: Depende la zona puedo enviarlo en Cabify/Uber envíos.

Para los artículos de mi suegra podés arreglar con ella.

Voy a seguir publicando cosas de mi suegra, pero lo está organizando así que probablemente vaya haciendo updates en este post. Te recomiendo que lo guardes y lo vayas siguiendo 😉

REFERENCIAS DE VENTAS POR LOS SIGUIENTES POST:

https://www.reddit.com/Mercadoreddit/comments/z12uyo/vendo_instrumentos_musicales_y_gear_de_audio/
https://www.reddit.com/Mercadoreddit/comments/12yvr6k/vendo_herramientas_geek_y_gear_tecnol%C3%B3gico/
https://www.reddit.com/Mercadoreddit/comments/10gkqrl/venta_gpus_xfx_amd_rx_570_8gb_evga_nvidia_geforce/

Eso es to-to-to-todo, amigos!

​
*Para los pagos en crypto se saca la cotización del p2p de Binance en el momento del pago

Introducción

https://preview.redd.it/4c4e6geyem2b1.jpg?width=2355&format=pjpg&auto=webp&s=8d994ddd8f74e21bf79736c5a9735a3e82ae04e4
Los aclamados 7HZ Salnotes Zero son unos IEM de un driver dinámico por lado que rompieron el mercado de los IEMs unos meses atrás, recibiendo el apoyo de grandes reviewers y siendo recomendados por muchísimos usuarios por su excelente performance a un precio más que aceptable ($20 USD en Argentina $24500)
Video reseña acá
Otras reseñas acá
​

Ranking (* = estrella): * * * * *

​

Pros	Contras
Timbre excepcional	Imagen por debajo del promedio
Buenos accesorios	A los graves les falta un poco de presencia
Tuning inofensivo para largas sesiones musicales
Posibilidad de adaptarse a varios géneros
Soundstage amplio y profundo

​
Aclaración:

• La reseña se basa en el uso exclusivo de los mismos durante una semana – Sesiones de 2 a 4 hs aprox.
• Géneros musicales preferidos: Heavy Metal, Música clásica, EDM – Toda la música es sin pérdida (mayor a 16bit – 44.1khz).
• Equipo usado: IFI Zen Air Can (AMP) + Fiio E10K (DAC).
• El producto reseñado fue pagado por mí.

Unboxing, construcción y confort

Caja simple pero esperada en este segmento de precio. Como en la mayoría de estas, al abrirla nos encontramos con el par de auriculares y debajo de ellos dos bolsas pequeñas: una con el cable tipo 2pin 0.78mm y otra con 5 pares extras de puntas de silicona.
https://preview.redd.it/ew2893bzem2b1.jpg?width=3705&format=pjpg&auto=webp&s=b530f119745ac2f6025a61bf0a450d08d0b438bb
La construcción de los auriculares en sí se siente barata. El driver de 10mm con diafragma compuesto de metal se encuentra protegido por un housing moldeado en plástico y con un faceplate metálico con las inscripciones de la marca y modelo. Un punto positivo de este tipo de construcción es la variedad de colores que se ofrecen para este modelo que son 6 en total: blanco, negro, celeste, rojo, rosa y naranja.
https://preview.redd.it/fjuoa5y0fm2b1.jpg?width=4000&format=pjpg&auto=webp&s=2547183ad0f31c8cbf260b04559cae06fab6913a
Pasando al cable, por el precio está muy bien. Tiene buena maleabilidad, no se enreda fácilmente y el conector de 3.5mm es recto, que alivia la tensión de la terminación del cable en este punto en comparación a los conectores en forma de “L”. Como puntos negativos de este encontramos que es un poco microfónico al rozar con la ropa y que tiene guías plásticas para las orejas que pueden resultar incómodas para algunos.
https://preview.redd.it/gt4n9jq2fm2b1.jpg?width=3579&format=pjpg&auto=webp&s=1ece65cc0ed60d7a9068ac6f5e821464980af594
Con respecto a las puntas de silicona, me sorprendió la cantidad que vienen incluidas (6 pares contando las que llevan puestas los IEMs). Algunas de estas son de “orificio amplio” como las de color naranja (retienen mejor frecuencias graves y agudas) y otras de un orificio más estrecho como las de color celeste (reducen las frecuencias agudas sin afectar los graves = más elevación de los graves)
Por último, el confort de estos auriculares me pareció excelente desde el primer día. Siempre lo usé con las puntas naranjas que son de tamaño pequeño (S) y tanto la forma del IEM como dichas puntas favorecieron a un sellado excepcional de mi oído externo, y son tan livianos y cómodos que puedo usarlos durante horas sin siquiera acomodarlos. Es una muy buena opción para aquel que necesite paz en ambientes ruidosos

Descripción de la respuesta en frecuencia

Créditos: https://crinacle.com/

• Subgraves con gran extensión y graves con correcta presencia
• Transición “suave” desde los graves a frecuencias medias
• Frecuencias medias siguiendo 1 a 1 curva Harman
• Agudos inofensivos con buena extensión y aire

Descripción subjetiva del sonido

https://preview.redd.it/y7ltp297fm2b1.jpg?width=2686&format=pjpg&auto=webp&s=c75272226b3ff57f03dbc408499e091215c56c3a
Graves
\rumble: frecuencia baja y profunda que puede ser más percibida que escuchada*
Subgraves con mucha autoridad lo cual queda demostrado en canciones como “Xanny” de Billie Eilish y ”Hot In It“ de Tiesto. La sensación de “rumble”* en estas y otras canciones es muy bueno, los subgraves se sienten en todo el pecho.
Por otro lado, los graves (>50-60 Hz a 200 Hz) estan un poco por detrás para mi gusto como queda demostrado en canciones de EDM como “Follow” de Martin Garrix. No obstante, esto evita que las frecuencias graves “molesten” a las frecuencias medias y haya una transición correcta entre estas
Medios
Escuché varios cantantes distintos para tener una buena referencia de este rango de la frecuencia. Freddie Mercury, Billie Eilish, Adele y Calamaro, en ninguno de estos artistas pude encontrar algo incorrecto con esta frecuencia.
Voces masculinas como femeninas se desenvuelven naturalmente teniendo una presencia más que adecuada, donde las voces femeninas tienen un poco más de autoridad como escuché en “Vivere” en la parte donde Bocceli canta en conjunto con Gerardina Trovato.
La articulación entre los distintos instrumentos y voces que ocupan este rango es muy buena no “molestándose” en ningún momento.
Agudos
En general las frecuencias agudas dejan un poco que desear para aquellos que les guste un tuning más brillante y con más cantidad de detalle. No obstante, esto es un punto muy positivo para sesiones de largas escuchas donde este IEM va a reproducir toda la biblioteca con una musicalidad excepcional. En “Black Magic” de Slayer (Live Undead), el platillo del baterista en los primeros 30 segundos nunca es ofensivo con el oído pero tiene buena presencia. En “Revelations” de Iron Maiden también la variedad de platillos que son ejecutados por el baterista durante los solos de guitarra se tienen presencia pero una muy tranquila sin ser agresivos ni brillantes.
Timbre
\Timbre: características distintivas entre los sonidos de los instrumentos/voces que nos permiten diferenciarlos entre sí.*
El timbre* de estos auriculares es algo que otras compañías tendrían que tomar nota. Entiendo que no es un tuning arriesgado al seguir la curva Harman pero los instrumentos se encuentran tan bien representados que a pesar de no ser el mejor IEM en términos de resolución/detalle se hacen comparables con otros que están muy por encima de su rango de precio gracias a la excelente ejecución del timbre. Todos los instrumentos “Invierno: Allegro non Molto” de Vivaldi - interpretada por Fabio Biondi, se distinguen excelentemente entre ellos, desde el violinista principal hasta los violonchelos y el contrabajo que acompañan al resto de violines.
Soundstage e imagen
\Imagen: precisión y claridad con la que se pueden ubicar sonidos en la mezcla.*
Como se mencionó anteriormente en la descripción de la respuesta en frecuencia, el soundstage o espacialidad del sonido está por encima del promedio. Canciones como “The Great Unknown” de Iron Maiden y “Bicycle Race” de Queen sacan a la luz que estos auriculares tienen un soundstage ancho y que puede ser profundo cuando debe serlo. En la segunda canción mencionada, se crea una escena tridimensional muy bien lograda ubicando a todos los coristas y la batería por detrás de Freddie, con uno de los platillos teniendo una presencia característica ubicándose atrás y a la derecha durante el estribillo.
Con respecto a la imagen*, este es uno de los pocos puntos débiles que le veo a los Zero. En “Alta Suciedad” de Calamaro me es difícil discernir entre las guitarras derecha e izquierda que tocan en la banda. Lo mismo sucede durante la introducción de la canción de Iron Maiden mencionada en el párrafo anterior.

7HZ Salnotes Zero vs KZ DQ6

Decidí hacer una breve comparación entre estos dos modelos dado a que se encuentran rondando el mismo rango de precio tanto internacionalmente como en Argentina (7hz Salnotes Zero al día de hoy: $24500 pesos argentinos o $20 USD - KZ DQ6 al día de hoy: $23500 pesos argentinos o $20 USD)
Créditos: https://crinacle.com/

• DQ6 tiene más punch y rumble por tener una elevación más pronunciada en las frecuencias graves. Son comparables en los subgraves, Zero con un poco mejor de extensión en este rango.
• La transición más “correcta” entre los graves y los medios hace que las voces e instrumentos suenen un poco más naturales en los 7hz en comparación.
• Los agudos son dos polos opuestos en mi experiencia: los DQ6 tienen unos agudos brillantes por momentos que ayudan a crear esa sensación de detalle pero a cambio de pequeñas sibilancias molestas, mientras que los Zero tienen unos agudos más relajados/oscuros que no son tan detallados pero ayudan a su musicalidad.

Conclusión

Viendo el nuevo segmento de ranking que incluí creo que es bastante obvio que esta es un producto simplemente fácil de recomendar: buen confort, tuning impecable por el precio, buena cantidad de accesorios y de respetable calidad por $20 USD. Los pocos puntos negativos que mencioné durante mi análisis claramente no alcanzan para bajar este producto del pedestal que se merece estar.

Introducción

https://preview.redd.it/k78ip8b8cm2b1.jpg?width=2355&format=pjpg&auto=webp&s=a03eb2c26f9264c9fe358bdb1661d220612b3458
Los aclamados 7HZ Salnotes Zero son unos IEM de un driver dinámico por lado que rompieron el mercado de los IEMs unos meses atrás, recibiendo el apoyo de grandes reviewers y siendo recomendados por muchísimos usuarios por su excelente performance a un precio más que aceptable ($20 USD en Argentina $24500)
Video reseña acá
Otras reseñas acá
​

Ranking (* = estrella): * * * * *

​

Pros	Contras
Timbre excepcional	Imagen por debajo del promedio
Buenos accesorios	A los graves les falta un poco de presencia
Tuning inofensivo para largas sesiones musicales
Posibilidad de adaptarse a varios géneros
Soundstage amplio y profundo

​
Aclaración:

• La reseña se basa en el uso exclusivo de los mismos durante una semana – Sesiones de 2 a 4 hs aprox.
• Géneros musicales preferidos: Heavy Metal, Música clásica, EDM – Toda la música es sin pérdida (mayor a 16bit – 44.1khz).
• Equipo usado: IFI Zen Air Can (AMP) + Fiio E10K (DAC).
• El producto reseñado fue pagado por mí.

Unboxing, construcción y confort

Caja simple pero esperada en este segmento de precio. Como en la mayoría de estas, al abrirla nos encontramos con el par de auriculares y debajo de ellos dos bolsas pequeñas: una con el cable tipo 2pin 0.78mm y otra con 5 pares extras de puntas de silicona.
https://preview.redd.it/1mhhkkagdm2b1.jpg?width=3705&format=pjpg&auto=webp&s=09cf283fe48eca5fc20cc030ac75504a85ce17d8
La construcción de los auriculares en sí se siente barata. El driver de 10mm con diafragma compuesto de metal se encuentra protegido por un housing moldeado en plástico y con un faceplate metálico con las inscripciones de la marca y modelo. Un punto positivo de este tipo de construcción es la variedad de colores que se ofrecen para este modelo que son 6 en total: blanco, negro, celeste, rojo, rosa y naranja.
https://preview.redd.it/c4iebjnhdm2b1.jpg?width=4000&format=pjpg&auto=webp&s=77171e3629ca85d9024aa04b150d51e0f620d9ab
Pasando al cable, por el precio está muy bien. Tiene buena maleabilidad, no se enreda fácilmente y el conector de 3.5mm es recto, que alivia la tensión de la terminación del cable en este punto en comparación a los conectores en forma de “L”. Como puntos negativos de este encontramos que es un poco microfónico al rozar con la ropa y que tiene guías plásticas para las orejas que pueden resultar incómodas para algunos.
https://preview.redd.it/8wuxs24jdm2b1.jpg?width=3579&format=pjpg&auto=webp&s=7bf42cac51914ced0a7286a3d80594a8dbbc69e4
Con respecto a las puntas de silicona, me sorprendió la cantidad que vienen incluidas (6 pares contando las que llevan puestas los IEMs). Algunas de estas son de “orificio amplio” como las de color naranja (retienen mejor frecuencias graves y agudas) y otras de un orificio más estrecho como las de color celeste (reducen las frecuencias agudas sin afectar los graves = más elevación de los graves)
Por último, el confort de estos auriculares me pareció excelente desde el primer día. Siempre lo usé con las puntas naranjas que son de tamaño pequeño (S) y tanto la forma del IEM como dichas puntas favorecieron a un sellado excepcional de mi oído externo, y son tan livianos y cómodos que puedo usarlos durante horas sin siquiera acomodarlos. Es una muy buena opción para aquel que necesite paz en ambientes ruidosos

Descripción de la respuesta en frecuencia

Créditos: https://crinacle.com/

• Subgraves con gran extensión y graves con correcta presencia
• Transición “suave” desde los graves a frecuencias medias
• Frecuencias medias siguiendo 1 a 1 curva Harman
• Agudos inofensivos con buena extensión y aire

Descripción subjetiva del sonido

https://preview.redd.it/akopvh0pem2b1.jpg?width=2686&format=pjpg&auto=webp&s=434a71d1a819477e01a7fa12284899e2cd2317b3
Graves
\rumble: frecuencia baja y profunda que puede ser más percibida que escuchada*
Subgraves con mucha autoridad lo cual queda demostrado en canciones como “Xanny” de Billie Eilish y ”Hot In It“ de Tiesto. La sensación de “rumble”* en estas y otras canciones es muy bueno, los subgraves se sienten en todo el pecho.
Por otro lado, los graves (>50-60 Hz a 200 Hz) estan un poco por detrás para mi gusto como queda demostrado en canciones de EDM como “Follow” de Martin Garrix. No obstante, esto evita que las frecuencias graves “molesten” a las frecuencias medias y haya una transición correcta entre estas
Medios
Escuché varios cantantes distintos para tener una buena referencia de este rango de la frecuencia. Freddie Mercury, Billie Eilish, Adele y Calamaro, en ninguno de estos artistas pude encontrar algo incorrecto con esta frecuencia.
Voces masculinas como femeninas se desenvuelven naturalmente teniendo una presencia más que adecuada, donde las voces femeninas tienen un poco más de autoridad como escuché en “Vivere” en la parte donde Bocceli canta en conjunto con Gerardina Trovato.
La articulación entre los distintos instrumentos y voces que ocupan este rango es muy buena no “molestándose” en ningún momento.
Agudos
En general las frecuencias agudas dejan un poco que desear para aquellos que les guste un tuning más brillante y con más cantidad de detalle. No obstante, esto es un punto muy positivo para sesiones de largas escuchas donde este IEM va a reproducir toda la biblioteca con una musicalidad excepcional. En “Black Magic” de Slayer (Live Undead), el platillo del baterista en los primeros 30 segundos nunca es ofensivo con el oído pero tiene buena presencia. En “Revelations” de Iron Maiden también la variedad de platillos que son ejecutados por el baterista durante los solos de guitarra se tienen presencia pero una muy tranquila sin ser agresivos ni brillantes.
Timbre
\Timbre: características distintivas entre los sonidos de los instrumentos/voces que nos permiten diferenciarlos entre sí.*
El timbre* de estos auriculares es algo que otras compañías tendrían que tomar nota. Entiendo que no es un tuning arriesgado al seguir la curva Harman pero los instrumentos se encuentran tan bien representados que a pesar de no ser el mejor IEM en términos de resolución/detalle se hacen comparables con otros que están muy por encima de su rango de precio gracias a la excelente ejecución del timbre. Todos los instrumentos “Invierno: Allegro non Molto” de Vivaldi - interpretada por Fabio Biondi, se distinguen excelentemente entre ellos, desde el violinista principal hasta los violonchelos y el contrabajo que acompañan al resto de violines.
Soundstage e imagen
\Imagen: precisión y claridad con la que se pueden ubicar sonidos en la mezcla.*
Como se mencionó anteriormente en la descripción de la respuesta en frecuencia, el soundstage o espacialidad del sonido está por encima del promedio. Canciones como “The Great Unknown” de Iron Maiden y “Bicycle Race” de Queen sacan a la luz que estos auriculares tienen un soundstage ancho y que puede ser profundo cuando debe serlo. En la segunda canción mencionada, se crea una escena tridimensional muy bien lograda ubicando a todos los coristas y la batería por detrás de Freddie, con uno de los platillos teniendo una presencia característica ubicándose atrás y a la derecha durante el estribillo.
Con respecto a la imagen*, este es uno de los pocos puntos débiles que le veo a los Zero. En “Alta Suciedad” de Calamaro me es difícil discernir entre las guitarras derecha e izquierda que tocan en la banda. Lo mismo sucede durante la introducción de la canción de Iron Maiden mencionada en el párrafo anterior.

7HZ Salnotes Zero vs KZ DQ6

Decidí hacer una breve comparación entre estos dos modelos dado a que se encuentran rondando el mismo rango de precio tanto internacionalmente como en Argentina (7hz Salnotes Zero al día de hoy: $24500 pesos argentinos o $20 USD - KZ DQ6 al día de hoy: $23500 pesos argentinos o $20 USD)
Créditos: https://crinacle.com/

• DQ6 tiene más punch y rumble por tener una elevación más pronunciada en las frecuencias graves. Son comparables en los subgraves, Zero con un poco mejor de extensión en este rango.
• La transición más “correcta” entre los graves y los medios hace que las voces e instrumentos suenen un poco más naturales en los 7hz en comparación.
• Los agudos son dos polos opuestos en mi experiencia: los DQ6 tienen unos agudos brillantes por momentos que ayudan a crear esa sensación de detalle pero a cambio de pequeñas sibilancias molestas, mientras que los Zero tienen unos agudos más relajados/oscuros que no son tan detallados pero ayudan a su musicalidad.

Conclusión

Viendo el nuevo segmento de ranking que incluí creo que es bastante obvio que esta es un producto simplemente fácil de recomendar: buen confort, tuning impecable por el precio, buena cantidad de accesorios y de respetable calidad por $20 USD. Los pocos puntos negativos que mencioné durante mi análisis claramente no alcanzan para bajar este producto del pedestal que se merece estar.

https://preview.redd.it/yo8hsm1aah2b1.png?width=3500&format=png&auto=webp&s=ed1f761c1058266115f8a4b91c0fb30170d48ddb
Pan American Silver Corp. (NYSE: PAAS) (TSX: PAAS) ("Pan American" or the "Company") today reported unaudited results for the quarter ended March 31, 2023 ("Q1 2023").
"Pan American reported solid results for the first quarter of 2023, with adjusted earnings of $0.10 per share," said Michael Steinmann, President and Chief Executive Officer. "Going forward, Pan American will be a significantly larger, more diversified company following our acquisition of Yamana. Our guidance for 2023 demonstrates the positive impact of the four new mines on production and costs, and we are excited by the growth opportunities the combined portfolio presents."
On March 31, 2023, Pan American completed its previously announced acquisition of all of the issued and outstanding common shares of Yamana Gold Inc. ("Yamana"), following the sale by Yamana of its Canadian assets to Agnico Eagle Mines Limited, by way of a plan of arrangement under the Canada Business Corporations Act (the "Yamana transaction"). The Yamana transaction added four producing mines to Pan American's portfolio: the Jacobina mining complex in Brazil, the El Peñon and Minera Florida mines in Chile, and the Cerro Moro mine in Argentina ("Acquired Operations"), plus several exploration and development projects in Chile, Brazil and Argentina. Operating and financial results reported in this news release, except for the financial position as at March 31, 2023, reflect only Pan American's original mines, specifically: La Colorada, Huaron, San Vicente, Manantial Espejo, Timmins, Shahuindo, La Arena and Dolores (the "Original Assets").
The following highlights for Q1 2023 include certain measures that are not generally accepted accounting principle ("non-GAAP") financial measures. Please refer to the section titled “Alternative Performance (Non-GAAP) Measures” at the end of this news release for further information on these measures.
Consolidated Q1 2023 Highlights:

• Silver production of 3.9 million ounces and gold production of 122.7 thousand ounces. As previously disclosed, Manantial Espejo has been placed on care and maintenance following the completion of mining at the end of 2022; some residual production was recorded for Q1 2023.
• Revenue was $390.3 million, inclusive of a negative $3.8 million price adjustment on open concentrate shipments.
• Net earnings of $16.5 million ($0.08 basic earnings per share), including $18.9 million in transaction and integration costs related to the Yamana transaction and $12.7 million in severance provisions. Adjusted earnings were $21.2 million ($0.10 basic adjusted earnings per share).
• Cash flow from operations of $51.3 million, net of $30.7 million in tax payments.
• Silver Segment Cash Costs and All-in Sustaining Costs ("AISC") per silver ounce of $12.19 and $14.13, respectively. Excluding Net Realizable Value ("NRV") inventory adjustments, Silver Segment AISC was $14.11 per ounce.
• Gold Segment Cash Costs and AISC per gold ounce of $1,120 and $1,196, respectively. Excluding NRV inventory adjustments, Gold Segment AISC was $1,361 per ounce.
• Pan American's financial position as at March 31, 2023, incorporates the assets and liabilities Pan American assumed through the Yamana transaction. As at March 31, 2023, Pan American had working capital of $826.6 million, inclusive of cash and short-term investment balances of $513.1 million ($204.7 million related to the Minera Agua Rica Alumbrera ("MARA") project in Argentina), as well as $425 million available under its $750 million revolving sustainability-linked credit facility ("SL-Credit Facility"). Total debt of $1,187.0 million relates to the SL-Credit Facility, construction loans and leases, and two senior notes Pan American assumed through the Yamana transaction: $500 million with a coupon of 2.63% maturing in 2031 and $283 million with a coupon of 4.625% maturing in 2027. Moody's Investors Service and S&P Global have assigned Pan American with an investment grade credit rating.
• A cash dividend of $0.10 per common share with respect to Q1 2023 was previously declared on March 24, 2023, payable on or about May 12, 2023, to holders of record of Pan American’s common shares as of the close of markets on April 14, 2023. The dividends are eligible dividends for Canadian income tax purposes. Pan American selected that record and payment date to harmonize its dividend with respect to Q1 2023 with Yamana’s normal course dividend timing for payment of a first quarter dividend. Subsequent dividends to be declared by Pan American are expected to follow Pan American's previous schedule of dividend payments.
• Two ILO 169 consultation meetings for the Escobal mine were held in Q1 2023, as well as several working meetings between Guatemala's Ministry of Energy and Mines and Xinka Indigenous community representatives. At this time, no date has been set for a potential restart of operations at Escobal.

https://preview.redd.it/pg0leu9aah2b1.png?width=720&format=png&auto=webp&s=dc6d5ce4397e4a059550c5dd94838266b2fe516b
(1) Per share amounts are based on basic weighted average common shares.
(2) Non-GAAP measure; please refer to the "Alternative Performance (non-GAAP) Measures" section of this news release for further information on these measures.
(3) Metal prices stated are inclusive of final settlement adjustments on concentrate sales.
Cash Costs, AISC, adjusted earnings, basic adjusted earnings per share, sustaining and non-sustaining capital, working capital, total debt and net cash are non-GAAP financial measures. Please refer to the "Alternative Performance (non-GAAP) Measures" section of this news release for further information on these measures.
This news release should be read in conjunction with Pan American's unaudited Condensed Interim Consolidated Financial Statements and our Management's Discussion and Analysis ("MD&A") for the three months ended March 31, 2023. This material is available on Pan American’s website at panamericansilver.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov
CONFERENCE CALL AND WEBCAST
https://preview.redd.it/e5785wbaah2b1.png?width=720&format=png&auto=webp&s=41beee937e97d74928df4dbc38ad1ab382388145
The live webcast, presentation slides and the report for the first quarter of 2023 will be available at https://www.panamericansilver.com/invest/events-and-presentations/
2023 GUIDANCE
The following provides Management's 2023 guidance, as at May 10, 2023. Relative to the guidance provided on April 27, 2023, the only revision is an increase in estimated project capital expenditures to a range of $95 million to $105 million from the previous range of $75 million to $85 million. The revised range reflects an updated estimate to complete the preliminary economic assessment studies and to advance the exploration drilling for the La Colorada Skarn project.
2023 General and Administrative, Care and Maintenance, and Exploration Expense Forecast
2023 General and Administrative expenses are estimated to total between $75 to $80 million, and reflects increased personnel following the Yamana transaction, increased regulatory and insurance costs, and a normalized year of stock based compensation, which was lower than assumed in 2022 due to share price performance.
2023 Care and Maintenance costs are estimated to total $98 to $109 million, which reflects expenditures for Escobal, the MARA project, Manantial Espejo and Morococha.
2023 Exploration Expense is estimated to total $14 to $16 million for regional greenfield expenditures. The expenditures relating to near-mine exploration are included in the sustaining and project capital amounts provided in the Capital Expenditures Forecast table below.
The production and cost guidance provided in the following tables reflect the contribution from the Acquired Operations for the nine-month period from March 31, 2023 to December 31, 2023, and the full 12-month period of 2023 for Pan American's Original Assets. Please see our MD&A for the period ending March 31, 2023, for a more detailed breakdown of the guidance, including by individual mine and on a quarterly basis for 2023. These estimates are forward-looking statements and information that are subject to the cautionary note associated with forward-looking statements and information at the end of this news release.
https://preview.redd.it/3729czcaah2b1.png?width=720&format=png&auto=webp&s=2ae2c0b5e4a738529b58c4d64cdedaae34f4183a
https://preview.redd.it/9jvfmzdaah2b1.png?width=720&format=png&auto=webp&s=96456af7e1f873939a912443068e41a54058a0a8
(1) 2023 production and AISC forecasts reflect ownership of the Acquired Operations for the nine-month period from March 31 to December 31, 2023 and the full 12 months for Pan American's Original Assets.
(2) Cash Costs and AISC are non-GAAP measures. Please refer to the "Alternative Performance (non-GAAP) Measures" section of this news release for further information on these measures. The AISC forecast assumes metal prices of $22.00/oz for silver, $1,850/oz for gold, $3,000/tonne ($1.36/lb) for zinc, $2,100/tonne ($0.95/lb) for lead, and $8,000/tonne ($3.63/lb) for copper; and average annual exchange rates relative to 1 USD of 18.75 for the Mexican peso ("MXN"), 3.75 for the Peruvian sol ("PEN"), 270.00 for the Argentine peso ("ARS"), 7.00 for the Bolivian boliviano ("BOB"), $1.33 for the Canadian dollar ("CAD"), $800.00 for the Chilean peso ("CLP") and $5.00 for the Brazilian real ("BRL").
https://preview.redd.it/m9i8qnfaah2b1.png?width=720&format=png&auto=webp&s=fccb59f6cbe2bc85bac19463eabea645e93dc4f7
About Pan American
Pan American is a leading producer of precious metals in the Americas, operating silver and gold mines in Canada, Mexico, Peru, Bolivia, Argentina, Chile and Brazil. We also own the Escobal mine in Guatemala that is currently not operating, and we hold interests in exploration and development projects, including the Minera Agua Rica Alumbrera ("MARA") project in Argentina. We have been operating in the Americas for nearly three decades, earning an industry-leading reputation for sustainability performance, operational excellence and prudent financial management. We are headquartered in Vancouver, B.C. and our shares trade on New York Stock Exchange and the Toronto Stock Exchange under the symbol "PAAS". Learn more at https://www.panamericansilver.com/
Technical Information
Scientific and technical information contained in this news release have been reviewed and approved by Martin Wafforn, P.Eng., Senior Vice President Technical Services and Process Optimization, and Christopher Emerson, FAusIMM, Vice President Exploration and Geology, each of whom are Qualified Persons, as the term is defined in Canadian National Instrument 43-101 - Standards of Disclosure for Mineral Projects
For additional information about Pan American's material mineral properties, please refer to Pan American’s Annual Information Form dated February 22, 2023, filed at www.sedar.com , or the Company's most recent Form 40-F filed with the Securities and Exchange Commission.
Alternative Performance (Non-GAAP) Measures
In this news release, we refer to measures that are non-GAAP financial measures. These measures are widely used in the mining industry as a benchmark for performance, but do not have a standardized meaning as prescribed by IFRS as an indicator of performance, and may differ from methods used by other companies with similar descriptions. These non-GAAP financial measures include:

• Cash Costs. Pan American's method of calculating cash costs may differ from the methods used by other entities and, accordingly, Pan American's Cash Costs may not be comparable to similarly titled measures used by other entities. Investors are cautioned that Cash Costs should not be construed as an alternative to production costs, depreciation and amortization, and royalties determined in accordance with IFRS as an indicator of performance.
• Adjusted earnings and basic adjusted earnings per share. Pan American believes that these measures better reflect normalized earnings as they eliminate items that in management's judgment are subject to volatility as a result of factors, which are unrelated to operations in the period, and/or relate to items that will settle in future periods.
• All-in Sustaining Costs per silver or gold ounce sold, net of by-product credits ("AISC"). Pan American has adopted AISC as a measure of its consolidated operating performance and its ability to generate cash from all operations collectively, and Pan American believes it is a more comprehensive measure of the cost of operating our consolidated business than traditional cash costs per payable ounce, as it includes the cost of replacing ounces through exploration, the cost of ongoing capital investments (sustaining capital), general and administrative expenses, as well as other items that affect Pan American's consolidated earnings and cash flow.
• Total debt is calculated as the total current and non-current portions of: long-term debt, finance lease liabilities and loans payable. Total debt does not have any standardized meaning prescribed by GAAP and is therefore unlikely to be comparable to similar measures presented by other companies. Pan American and certain investors use this information to evaluate the financial debt leverage of Pan American.
• Working capital is calculated as current assets less current liabilities. Working capital does not have any standardized meaning prescribed by GAAP and is therefore unlikely to be comparable to similar measures presented by other companies. Pan American and certain investors use this information to evaluate whether Pan American is able to meet its current obligations using its current assets.
• Total available liquidity is calculated as the sum of Cash and cash equivalents, Short-term Investments, and the amount available on the Credit Facility. Total available liquidity does not have any standardized meaning prescribed by GAAP and is therefore unlikely to be comparable to similar measures presented by other companies. Pan American and certain investors use this information to evaluate the liquid assets available to Pan American.

Readers should refer to the "Alternative Performance (non-GAAP) Measures" section of Pan American’s Management's Discussion and Analysis for the period ended December 31, 2022, for a more detailed discussion of these and other non-GAAP measures and their calculation.
Cautionary Note Regarding Forward-Looking Statements and Information
Certain of the statements and information in this news release constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian provincial securities laws. All statements, other than statements of historical fact, are forward-looking statements or information. Forward-looking statements or information in this news release relate to, among other things: future financial or operational performance, including our estimated production of silver, gold and other metals forecasted for 2023, our estimated Cash Costs and AISC, and our sustaining and project capital expenditures in 2023; whether Pan American is able to realize synergies or obtain the positive impact from the four new mines resulting from the Yamana transaction; estimated recoverable amounts of cash generating units; expectations with respect to mineral grades and the impact of any variations relative to actual grades experienced; the anticipated dividend payment date of May 12, 2023; future anticipated prices for gold, silver and other metals and assumed foreign exchange rates; and Pan American’s plans and expectations for its properties and operations.
These forward-looking statements and information reflect Pan American’s current views with respect to future events and are necessarily based upon a number of assumptions that, while considered reasonable by Pan American, are inherently subject to significant operational, business, economic and regulatory uncertainties and contingencies. These assumptions include: the impact of inflation and disruptions to the global, regional and local supply chains; the world-wide economic and social impact of COVID-19 and the duration and extent of the COVID-19 pandemic and related restrictions;; tonnage of ore to be mined and processed; future anticipated prices for gold, silver and other metals and assumed foreign exchange rates; the timing and impact of planned capital expenditure projects, including anticipated sustaining, project, and exploration expenditures; the ongoing impact and timing of the court-mandated ILO 169 consultation process in Guatemala; ore grades and recoveries; capital, decommissioning and reclamation estimates; our mineral reserve and mineral resource estimates and the assumptions upon which they are based; prices for energy inputs, labour, materials, supplies and services (including transportation); no labour-related disruptions at any of our operations; no unplanned delays or interruptions in scheduled production; all necessary permits, licenses and regulatory approvals for our operations are received in a timely manner; our ability to secure and maintain title and ownership to mineral properties and the surface rights necessary for our operations; whether Pan American is able to maintain a strong financial condition and have sufficient capital, or have access to capital through our corporate sustainability-linked credit facility or otherwise, to sustain our business and operations; and our ability to comply with environmental, health and safety laws. The foregoing list of assumptions is not exhaustive.
Pan American cautions the reader that forward-looking statements and information involve known and unknown risks, uncertainties and other factors that may cause actual results and developments to differ materially from those expressed or implied by such forward-looking statements or information contained in this news release and Pan American has made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation: the duration and effect of local and world-wide inflationary pressures and the potential for economic recessions; the duration and effects of COVID-19, and any other pandemics on our operations and workforce, and the effects on global economies and society; fluctuations in silver, gold and base metal prices; fluctuations in prices for energy inputs, labour, materials, supplies and services (including transportation); fluctuations in currency markets (such as the PEN, MXN, ARS, BOB, GTQ, CAD, CLP and BRL versus the USD); operational risks and hazards inherent with the business of mining (including environmental accidents and hazards, industrial accidents, equipment breakdown, unusual or unexpected geological or structural formations, cave-ins, flooding and severe weather); risks relating to the credit worthiness or financial condition of suppliers, refiners and other parties with whom Pan American does business; inadequate insurance, or inability to obtain insurance, to cover these risks and hazards; employee relations; relationships with, and claims by, local communities and indigenous populations; our ability to obtain all necessary permits, licenses and regulatory approvals in a timely manner; changes in laws, regulations and government practices in the jurisdictions where we operate, including environmental, export and import laws and regulations; changes in national and local government, legislation, taxation, controls or regulations and political, legal or economic developments in Canada, the United States, Mexico, Peru, Argentina, Bolivia, Guatemala, Chile, Brazil or other countries where Pan American may carry on business, including legal restrictions relating to mining, including in Chubut, Argentina, risks relating to expropriation and risks relating to the constitutional court-mandated ILO 169 consultation process in Guatemala; diminishing quantities or grades of mineral reserves as properties are mined; increased competition in the mining industry for equipment and qualified personnel; those factors identified under the caption "Risks Related to Pan American's Business" in Pan American's most recent form 40-F and Annual Information Form filed with the United States Securities and Exchange Commission and Canadian provincial securities regulatory authorities, respectively; and those factors identified under the caption "Risks of the Business" in Yamana's most recent form 40-F and Annual Information Form filed with the United States Securities and Exchange Commission and Canadian provincial securities regulatory authorities, respectively. Although Pan American has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated, described or intended. Investors are cautioned against undue reliance on forward-looking statements or information. Forward-looking statements and information are designed to help readers understand management's current views of our near and longer term prospects and may not be appropriate for other purposes. Pan American does not intend, nor does it assume any obligation to update or revise forward-looking statements or information, whether as a result of new information, changes in assumptions, future events or otherwise, except to the extent required by applicable law.
Cautionary Note to US Investors
This news release has been prepared in accordance with the requirements of Canadian National Instrument 43-101 (the "NI 43-101") and the Canadian Institute of Mining, Metallurgy and Petroleum Definition Standards, which differ from the requirements of U.S. securities laws. NI 43-101 is a rule developed by the Canadian Securities Administrators that establishes standards for all public disclosure an issuer makes of scientific and technical information concerning mineral projects.
Canadian public disclosure standards, including NI 43-101, differ significantly from the requirements of the United States Securities and Exchange Commission (the "SEC"), and information concerning mineralization, deposits, mineral reserve and resource information contained or referred to herein may not be comparable to similar information disclosed by U.S. companies.
​
View source version on businesswire.com: https://www.businesswire.com/news/home/20230510005398/en/
For more information:
Siren Fisekci
VP, Investor Relations & Corporate Communications
Ph: 604-806-3191
Email: [[email protected]](mailto:[email protected])
https://preview.redd.it/g40wz3haah2b1.png?width=4000&format=png&auto=webp&s=723449a8508ddf9d54deb09fb8504eb77c672551

Universal Site Links
PAN AMERICAN SILVER CORP
STOCK METAL DATABASE
ADD TICKER TO THE DATABASE
www.reddit.com/Treaty_Creek
REPORT AN ERROR

https://preview.redd.it/k5ezh5koxy1b1.png?width=3500&format=png&auto=webp&s=1311911cd34300183546473dd50449f6faaad288
(TheNewswire)
https://preview.redd.it/bwg1vvmoxy1b1.png?width=720&format=png&auto=webp&s=9899251a46dc068cccf141f2e24f77db02b34309

Toronto, ON

TheNewswire

May 25, 2023 - AbraSilver Resource Corp. (TSX.V:ABRA ) ( OTC:ABBRF) (“ AbraSilver ” or the “ Company ”) is pleased to announce the latest assay results from the ongoing Phase III diamond drilling program on the Company’s wholly-owned Diablillos property in Salta Province, Argentina (“Diablillos” or the “Project”). The Company is also pleased to announce that the Phase III program is being increased as mineralization at the JAC zone remains open.
Drilling at the JAC zone continues to consistently intersect high-grade silver oxide mineralization, with associated gold in some areas, at shallow depths, as well as underlying copper and silver mineralization in sulphides.
Notably, drill hole DDH 23-029 encountered silver mineralization in oxides to the west of the main JAC mineralized zone, which was drilled to test an extension of the magnetic anomaly associated with the mineralization at JAC. This mineralization is hosted in granitic basement rocks under the andesite volcanics and, consequently, opens up potential for further mineralized zones. Additionally, the JAC zone continues to remain open along strike towards the southwest and in other directions.
The latest assay result highlights are summarized in Table 1 below.
Table 1 – Diablillos Drill Result Highlights in JAC Zone
(Intercepts greater than 2,000 gram-metres AgEq shown in bold text) :
https://preview.redd.it/ih3usunoxy1b1.png?width=720&format=png&auto=webp&s=0ba4778f04da8b267b3fe5221321b19f19891f8b
Note: All results in this news release are rounded. Assays are uncut and undiluted. Widths are drilled widths, not true widths. True widths are estimated to be approximately 80% of the interval widths for oxides.
1 AgEq based on 81.9(Ag):1(Au) calculated using long-term prices of US$25.00/oz Ag and US$1,750/oz Au, and 73.5% process recovery for Ag, and 86.0% process recovery for Au as demonstrated in the Company’s Preliminary Economic Assessment in respect of Diablillos dated January 13, 2022, using formula: AgEq g/t = Ag g/t + Au g/t x (Gold Price/Silver Price) x (Gold Recovery/Silver Recovery).
John Miniotis, President and CEO, commented, “We continue to intercept excellent widths and grades of silver at JAC in practically every single drill hole. Additionally, we continue to see significant potential for new discoveries beyond the main JAC mineralized zone, as highlighted in hole DDH 23-029. Our drill results continue to confirm our belief that the new JAC zone is a major mineralized system, with significant exploration upside remaining to be discovered. For that reason, we are again increasing the amount of drilling being done as part of the Phase III program.”
Dave O’Connor, Chief Geologist, commented, “In addition to consistently encountering high-grade silver mineralization with associated gold at JAC, we are also intersecting underlying high-grade copper mineralization with associated silvegold in sulphides immediately beneath the oxides. It is now evident that the high-grade sulphide mineralization in zones beneath the base of oxidation is continuous for at least 2 km along the length of the Oculto-JAC system, representing an additional attractive exploration target, beyond the oxidized mineralization at JAC.”
Key takeaways from the latest JAC zone drill results include:

• DDH 23-024 was drilled to test continuity of the JAC Zone for resource estimation. The hole intersected multiple zones of silver mineralization in oxides, with 17.0 metres grading 828.9 g/t Ag from a downhole depth of 144.0 metres, including 5.0 metres grading 2,215.4 g/t Ag.
• DDH 23-025 was drilled to test continuity of the JAC Zone for resource estimation. The hole intersected significant silver and gold mineralization in oxides, including 79 metres at 237.6 g/t Ag and 0.15 g/t Au from 100.0 metres downhole.
  • Immediately beneath this high-grade oxide intercept, the hole encountered 30.5 metres grading 3.28% Cu and 96.6 g/t Ag in sulphide mineralization. This is the best copper intercept drilled at JAC to date on a grade-thickness basis, demonstrating the potential of high-grade feeder structures at JAC to host substantial sulphide mineralisation.
• DDH 23-026 was drilled to test the north-eastern extremity of the JAC Zone near the Oculto conceptual open pit, and encountered silver and gold mineralization in oxides, intersecting 19.0 metres grading 107.3 g/t Ag and 0.69 g/t Au from 131.0 metres downhole.
• DDH 23-027 was drilled to test the northern margin of the JAC Zone and intersected 59 metres grading 129.6 g/t Ag, including 4 metres grading 812.2 g/t Ag, starting from a downhole depth of only 56.0 metres.
• DDH 23-028 was drilled to test continuity of the JAC Zone for resource estimation. The hole encountered 24.5 metres grading 189.8 g/t Ag in the oxide/sulphide transition zone, including 3.0 metres grading 1,174.9 g/t Ag and 0.79% Cu in sulphides, starting from a downhole depth of 156.5 metres.
• DDH 23-029, was drilled beyond the JAC drill target area to explore for a possible new perpendicular zone of mineralization. The hole showed continuity of silver dominant mineralisation beyond the current southwestern margin of the JAC deposit and intersected 31.4 metres grading 174.4 g/t Ag in oxides starting from a downhole depth of 126.0 metres.
  • The hole is located on a zone of low magnetic intensity heading NW from the main JAC trend towards the Alpaca target where historical drilling intersected silver mineralisation. Additional drilling in this area will now be conducted.

Figure 1 – Plan View of Announced Drill Holes in JAC Zone
https://preview.redd.it/p860fxooxy1b1.png?width=737&format=png&auto=webp&s=fee4420ced0d2df5339f4b704ac9b9a74bff9afc
Figure 2 – Long Section Through Newly Announced Drill Holes in JAC Zone
https://preview.redd.it/ph979vqoxy1b1.png?width=739&format=png&auto=webp&s=0f66e3e5f2b81a5507c03fc1fc150adbb67c53fc
Exploration Update
Drilling activity at Diablillos remains focused on the recently discovered JAC zone which is located southwest of the conceptual open pit that constrains the current Mineral Resource estimate (“MRE”) on the main Oculto deposit (M&I MRE containing 1.3 Moz gold and 109 Moz silver – Table 2).
Two rigs have essentially completed drilling the planned 22,000-metre Phase III program with results demonstrating mineralization at the JAC zone over an area at least 800 metres by approximately 200 metres. As the JAC zone remains open in several directions, the Company now plans to drill at least an additional 15 holes as part of the Phase III program in order to define the limits of the high-grade silver mineralization in oxides. All Phase III drill holes will be incorporated into an updated MRE and will be included in a Pre-Feasibility Study on the Diablillos project, which the Company expects to complete in the second half of 2023.
Moreover, additional exploration targets have been identified to the southwest of the Oculto MRE based on the recently completed detailed ground magnetic survey. Some of these targets, including the Fantasma and Alpaca targets, will be drilled following the systematic drilling of the JAC zone.
Collar Data
https://preview.redd.it/7zy624soxy1b1.png?width=720&format=png&auto=webp&s=7b540c94c72e38a98aa507ca20941ddb7079f533
About Diablillos
The 80 km 2 Diablillos property is located in the Argentine Puna region - the southern extension of the Altiplano of southern Peru, Bolivia, and northern Chile - and was acquired from SSR Mining Inc. by the Company in 2016. There are several known mineral zones on the Diablillos property, with the Oculto zone being the most advanced with over 120,000 metres drilled to date. Oculto is a high-sulphidation epithermal silver-gold deposit derived from remnant hot springs activity following Tertiarty-age local magmatic and volcanic activity. Comparatively nearby examples of high sulphidation epithermal deposits include: Yanacocha (Peru); El Indio (Chile); Lagunas Nortes/Alto Chicama (Peru) Veladero (Argentina); and Filo del Sol (Argentina).
The most recent Mineral Resource estimate for the Oculto Deposit is shown in Table 2:
Table 2 - Oculto Mineral Resource Estimate – As of October 31, 2022
https://preview.redd.it/wggkc1toxy1b1.png?width=720&format=png&auto=webp&s=86fa93dd50de0aaf05ca9559794e6c58aaa52ad8
Notes: Effective October 31, 2022. Mineral Resources are not Mineral Reserves and have not demonstrated economic viability. The Mineral Resource estimate is N.I. 43-101 compliant and was prepared by Luis Rodrigo Peralta, B.Sc., FAusIMM CP(Geo), Independent Consultant. The mineralization estimated in the Mineral Resource is sub-horizontal with sub-vertical feeders and a reasonable prospect for eventual economic extraction by open pit methods. For additional information please see Technical Report on the Diablillos Project, Salta Province, Argentina, dated November 28, 2022, completed by Mining Plus, and available on www.SEDAR.com.
QA/QC and Core Sampling Protocols
AbraSilver applies industry standard exploration methodologies and techniques, and all drill core samples are collected under the supervision of the Company’s geologists in accordance with industry practices. Drill core is transported from the drill platform to the logging facility where drill data is compared and verified with the core in the trays. Thereafter, it is logged, photographed, and split by diamond saw prior to being sampled. Samples are then bagged, and quality control materials are inserted at regular intervals; these include blanks and certified reference materials as well as duplicate core samples which are collected in order to measure sample representivity. Groups of samples are then placed in large bags which are sealed with numbered tags in order to maintain a chain-of-custody during the transport of the samples from the project site to the laboratory.
All samples are received by the SGS offices in Salta who then dispatch the samples to the SGS preparation facility in San Juan. From there, the prepared samples are sent to the SGS laboratory in Lima, Peru where they are analyzed. All samples are analyzed using a multi-element technique consisting of a four acid digestion followed by ICP/AES detection, and gold is analyzed by 50g Fire Assay with an AAS finish. Silver results greater than 100g/t are reanalyzed using four acid digestion with an ore grade AAS finish.
Qualified Persons
David O’Connor P.Geo., Chief Geologist for AbraSilver, is the Qualified Person as defined by National Instrument 43-101 Standards of Disclosure for Mineral Projects, and he has reviewed and approved the scientific and technical information in this news release.
About AbraSilver
AbraSilver is an advanced-stage exploration company focused on rapidly advancing its 100%-owned Diablillos silver-gold project in the mining-friendly Salta province of Argentina. The current Measured and Indicated Mineral Resource estimate for Diablillos consists of 51.3 Mt grading 66g/t Ag and 0.79g/t Au, containing approximately 109Moz silver and 1.3Moz gold, with significant further upside potential based on recent exploration drilling. The Company is led by an experienced management team and has long-term supportive shareholders including Mr. Eric Sprott. In addition, AbraSilver owns a portfolio of earlier-stage copper-gold projects including the La Coipita copper-gold project in the San Juan province of Argentina. AbraSilver is listed on the TSX-V under the symbol “ABRA” and in the U.S. under the symbol “ABBRF”.
For further information please visit the AbraSilver Resource website at www.abrasilver.com , our LinkedIn page at , and follow us on Twitter at
Alternatively please contact:
John Miniotis, President and CEO
[[email protected]](mailto:[email protected])
Tel: +1 416-306-8334
Cautionary Statements
This news release includes certain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. All statements that address future plans, activities, events or developments that the Company believes, expects or anticipates will or may occur are forward-looking information. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. When considering this forward-looking information, readers should keep in mind the risk factors and other cautionary statements in the Company’s disclosure documents filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in the disclosure documents could cause actual events or results to differ materially from those described in any forward-looking information. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release
Copyright (c) 2023 TheNewswire - All rights reserved.
https://preview.redd.it/83a742uoxy1b1.png?width=4000&format=png&auto=webp&s=23477cdaf85d762b68932d6f14447a2ac1aca0ce

Universal Site Links
ABRASILVER RESOURCE CORP
STOCK METAL DATABASE
ADD TICKER TO THE DATABASE
www.reddit.com/Treaty_Creek
REPORT AN ERROR